IL297741A - Treatment and/or prevention of a disease or a syndrome related to a virus infection - Google Patents
Treatment and/or prevention of a disease or a syndrome related to a virus infectionInfo
- Publication number
- IL297741A IL297741A IL297741A IL29774122A IL297741A IL 297741 A IL297741 A IL 297741A IL 297741 A IL297741 A IL 297741A IL 29774122 A IL29774122 A IL 29774122A IL 297741 A IL297741 A IL 297741A
- Authority
- IL
- Israel
- Prior art keywords
- infection
- aat
- cov
- sars
- composition
- Prior art date
Links
- 230000009385 viral infection Effects 0.000 title claims description 245
- 208000011580 syndromic disease Diseases 0.000 title claims description 114
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 91
- 201000010099 disease Diseases 0.000 title claims description 87
- 238000011282 treatment Methods 0.000 title claims description 79
- 230000002265 prevention Effects 0.000 title claims description 42
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 380
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 338
- 239000000203 mixture Substances 0.000 claims description 129
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 125
- 239000012634 fragment Substances 0.000 claims description 111
- 102000035195 Peptidases Human genes 0.000 claims description 104
- 108091005804 Peptidases Proteins 0.000 claims description 104
- 239000004365 Protease Substances 0.000 claims description 102
- 108010074328 Interferon-gamma Proteins 0.000 claims description 97
- 241001678559 COVID-19 virus Species 0.000 claims description 96
- 229940096437 Protein S Drugs 0.000 claims description 95
- 101710198474 Spike protein Proteins 0.000 claims description 95
- 108090000623 proteins and genes Proteins 0.000 claims description 85
- 208000024891 symptom Diseases 0.000 claims description 81
- 108010029485 Protein Isoforms Proteins 0.000 claims description 77
- 102000001708 Protein Isoforms Human genes 0.000 claims description 77
- 230000037452 priming Effects 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 74
- 102000004169 proteins and genes Human genes 0.000 claims description 72
- 102100037850 Interferon gamma Human genes 0.000 claims description 63
- 206010061218 Inflammation Diseases 0.000 claims description 61
- 102000005962 receptors Human genes 0.000 claims description 61
- 108020003175 receptors Proteins 0.000 claims description 61
- 230000004054 inflammatory process Effects 0.000 claims description 60
- 241000700605 Viruses Species 0.000 claims description 56
- 108090000624 Cathepsin L Proteins 0.000 claims description 38
- 102000004961 Furin Human genes 0.000 claims description 35
- 108090001126 Furin Proteins 0.000 claims description 35
- 102000008070 Interferon-gamma Human genes 0.000 claims description 34
- 229960003130 interferon gamma Drugs 0.000 claims description 34
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 31
- 241000711573 Coronaviridae Species 0.000 claims description 29
- 102000004225 Cathepsin B Human genes 0.000 claims description 25
- 108090000712 Cathepsin B Proteins 0.000 claims description 25
- 208000027866 inflammatory disease Diseases 0.000 claims description 24
- 210000000653 nervous system Anatomy 0.000 claims description 23
- 108090000544 Proprotein convertase 1 Proteins 0.000 claims description 22
- 102000004142 Trypsin Human genes 0.000 claims description 22
- 108090000631 Trypsin Proteins 0.000 claims description 22
- 208000018737 Parkinson disease Diseases 0.000 claims description 21
- 239000012588 trypsin Substances 0.000 claims description 21
- 108010091175 Matriptase Proteins 0.000 claims description 20
- 208000024827 Alzheimer disease Diseases 0.000 claims description 19
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 19
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 19
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 19
- 239000002753 trypsin inhibitor Substances 0.000 claims description 19
- 201000006417 multiple sclerosis Diseases 0.000 claims description 15
- 230000000241 respiratory effect Effects 0.000 claims description 14
- 108010028275 Leukocyte Elastase Proteins 0.000 claims description 13
- 102000016799 Leukocyte elastase Human genes 0.000 claims description 13
- 210000004899 c-terminal region Anatomy 0.000 claims description 12
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
- 208000019423 liver disease Diseases 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 7
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- 238000001415 gene therapy Methods 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 238000010253 intravenous injection Methods 0.000 claims description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
- 239000002777 nucleoside Substances 0.000 claims description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 5
- 102000003996 Interferon-beta Human genes 0.000 claims description 5
- 108090000467 Interferon-beta Proteins 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 229960004461 interferon beta-1a Drugs 0.000 claims description 5
- 229960001388 interferon-beta Drugs 0.000 claims description 5
- 229950006348 sarilumab Drugs 0.000 claims description 5
- 229960003989 tocilizumab Drugs 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 3
- 239000007933 dermal patch Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 229940012356 eye drops Drugs 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 26
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 10
- 101710081722 Antitrypsin Proteins 0.000 claims 2
- 102000004172 Cathepsin L Human genes 0.000 claims 2
- 102000004085 Proprotein convertase 1 Human genes 0.000 claims 2
- 230000001475 anti-trypsic effect Effects 0.000 claims 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 355
- 210000004027 cell Anatomy 0.000 description 241
- 208000025721 COVID-19 Diseases 0.000 description 197
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 179
- 208000001528 Coronaviridae Infections Diseases 0.000 description 174
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 115
- 235000019419 proteases Nutrition 0.000 description 76
- 235000018102 proteins Nutrition 0.000 description 65
- 108090000765 processed proteins & peptides Proteins 0.000 description 63
- 210000002381 plasma Anatomy 0.000 description 58
- 230000000694 effects Effects 0.000 description 52
- 239000013598 vector Substances 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 34
- 239000005089 Luciferase Substances 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 33
- 102400001321 Cathepsin L Human genes 0.000 description 32
- 108060001084 Luciferase Proteins 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 26
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000000872 buffer Substances 0.000 description 23
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 22
- 239000000463 material Substances 0.000 description 22
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 206010036790 Productive cough Diseases 0.000 description 19
- 230000007502 viral entry Effects 0.000 description 19
- 208000006820 Arthralgia Diseases 0.000 description 18
- 206010013975 Dyspnoeas Diseases 0.000 description 18
- 208000000112 Myalgia Diseases 0.000 description 18
- 241001112090 Pseudovirus Species 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 241000004176 Alphacoronavirus Species 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 239000007983 Tris buffer Substances 0.000 description 12
- 210000000170 cell membrane Anatomy 0.000 description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
- 241000315672 SARS coronavirus Species 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- -1 IL-14 Proteins 0.000 description 10
- 241000713666 Lentivirus Species 0.000 description 10
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 10
- 206010037660 Pyrexia Diseases 0.000 description 10
- 241001493065 dsRNA viruses Species 0.000 description 10
- 206010016256 fatigue Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000003802 sputum Anatomy 0.000 description 10
- 208000024794 sputum Diseases 0.000 description 10
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 9
- 208000000059 Dyspnea Diseases 0.000 description 9
- 206010019233 Headaches Diseases 0.000 description 9
- 206010028813 Nausea Diseases 0.000 description 9
- 206010068319 Oropharyngeal pain Diseases 0.000 description 9
- 201000007100 Pharyngitis Diseases 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 9
- 206010040744 Sinus headache Diseases 0.000 description 9
- 208000036142 Viral infection Diseases 0.000 description 9
- 206010047700 Vomiting Diseases 0.000 description 9
- 235000009697 arginine Nutrition 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000006806 disease prevention Effects 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 208000013465 muscle pain Diseases 0.000 description 9
- 230000008693 nausea Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000008786 sensory perception of smell Effects 0.000 description 9
- 230000014860 sensory perception of taste Effects 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 230000008673 vomiting Effects 0.000 description 9
- 108091007505 ADAM17 Proteins 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 102000016387 Pancreatic elastase Human genes 0.000 description 8
- 108010067372 Pancreatic elastase Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000005284 excitation Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 210000002161 motor neuron Anatomy 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000494545 Cordyline virus 2 Species 0.000 description 6
- 241000709661 Enterovirus Species 0.000 description 6
- 206010044565 Tremor Diseases 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 238000009423 ventilation Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IKQRPFTXKQQLJF-IAHYZSEUSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-n-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound OC([C@@]1(O)C(=O)C=2[C@@H]([C@](C3=CC=CC(O)=C3C=2O)(C)O)C[C@H]1[C@@H](C1=O)N(C)C)=C1C(=O)NCN1CCCC1 IKQRPFTXKQQLJF-IAHYZSEUSA-N 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 206010002942 Apathy Diseases 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 241000008904 Betacoronavirus Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 208000032140 Sleepiness Diseases 0.000 description 5
- 206010041349 Somnolence Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000020442 loss of weight Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000003001 serine protease inhibitor Substances 0.000 description 5
- 231100000046 skin rash Toxicity 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000124740 Bocaparvovirus Species 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001505332 Polyomavirus sp. Species 0.000 description 4
- 101150069374 Serpina1 gene Proteins 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 150000001484 arginines Chemical class 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 3
- 101710139375 Corneodesmosin Proteins 0.000 description 3
- 206010050685 Cytokine storm Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000700586 Herpesviridae Species 0.000 description 3
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 3
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 244000309467 Human Coronavirus Species 0.000 description 3
- 241001428935 Human coronavirus OC43 Species 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 208000004554 Leishmaniasis Diseases 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 241000351643 Metapneumovirus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002740 Muscle Rigidity Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101710144127 Non-structural protein 1 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 102000007238 Transferrin Receptors Human genes 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 208000010710 hepatitis C virus infection Diseases 0.000 description 3
- 102000048657 human ACE2 Human genes 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000010901 lateral sclerosis Diseases 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 230000006724 microglial activation Effects 0.000 description 3
- 230000002025 microglial effect Effects 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000005727 virus proliferation Effects 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 101800001768 Exoribonuclease Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000711467 Human coronavirus 229E Species 0.000 description 2
- 241000482741 Human coronavirus NL63 Species 0.000 description 2
- 102000016252 Huntingtin Human genes 0.000 description 2
- 108050004784 Huntingtin Proteins 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710104976 Interferon gamma-related Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010067003 Interleukin-33 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027374 Mental impairment Diseases 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 101800000510 Non-structural protein 7 Proteins 0.000 description 2
- 101800000509 Non-structural protein 8 Proteins 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- 108010048233 Procalcitonin Proteins 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000009341 RNA Virus Infections Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 101800004575 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000724205 Rice stripe tenuivirus Species 0.000 description 2
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000008847 Serpin Human genes 0.000 description 2
- 108050000761 Serpin Proteins 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 101150054399 ace2 gene Proteins 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 108010079279 alpha 1-antitrypsin Portland Proteins 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 2
- 229960003870 bromhexine Drugs 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 2
- 229960000772 camostat Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000013377 clone selection method Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- KJLLKLRVCJAFRY-UHFFFAOYSA-N mebutizide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(C(C)C(C)CC)NC2=C1 KJLLKLRVCJAFRY-UHFFFAOYSA-N 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 description 2
- 230000001915 proofreading effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 241000114864 ssRNA viruses Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000007501 viral attachment Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009848 Cogwheel rigidity Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000004449 DNA Virus Infections Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241001461743 Deltacoronavirus Species 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010013976 Dyspraxia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000008920 Gammacoronavirus Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 241000963438 Gaussia <copepod> Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229940122604 HCV protease inhibitor Drugs 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101150043003 Htt gene Proteins 0.000 description 1
- 101000756400 Human T-cell leukemia virus 2 Protein Rex Proteins 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108091007973 Interleukin-36 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- SXTAYKAGBXMACB-DPVSGNNYSA-N L-methionine sulfoximine Chemical compound CS(=N)(=O)CC[C@H](N)C(O)=O SXTAYKAGBXMACB-DPVSGNNYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 description 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 description 1
- OFKKPUNNTZKBSR-VIFPVBQESA-N N(6)-(2,4-dinitrophenyl)-L-lysine Chemical compound OC(=O)[C@@H](N)CCCCNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OFKKPUNNTZKBSR-VIFPVBQESA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 101800000935 Non-structural protein 12 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101150001779 ORF1a gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 206010067206 Postural reflex impairment Diseases 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102000044437 S1 domains Human genes 0.000 description 1
- 108700036684 S1 domains Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101500025257 Severe acute respiratory syndrome coronavirus 2 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 101150037054 aat gene Proteins 0.000 description 1
- 230000004598 abnormal eye movement Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000009218 additive inhibitory effect Effects 0.000 description 1
- 108010016828 adenylyl sulfate-ammonia adenylyltransferase Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000025194 apoptotic cell clearance Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 229940035482 glassia Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 230000002324 hematogenic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 102000052502 human ELANE Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000005022 impaired gait Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 229940046732 interleukin inhibitors Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010047374 matriptase 2 Proteins 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- MQUQNUAYKLCRME-UHFFFAOYSA-N n-(4-chloro-3-oxo-1-phenylbutan-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-UHFFFAOYSA-N 0.000 description 1
- 230000007107 neurocognitive deficit Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000001909 oculomotor nerve paralysis Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940090668 parachlorophenol Drugs 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940126731 protein tyrosine phosphatase inhibitor Drugs 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000004599 slow eye movement Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
FIELD OF THE INVENTION The present invention provides compositions and methods for the treatment and/or prevention of disease or syndrome related to a virus infection. The invention further relates to methods for determining the susceptibility of a subject for such a treatment as well as a method for determining the amount of the composition required for an effective treatment.
BACKGROUND OF THE INVENTION Viruses, such as for example Coronaviruses, cause diseases in animals and humans around the world. Coronaviruses are RNA viruses.
Human coronaviruses (HCoV) are mainly known to cause infections of the upper and lower respiratory tract. Examples for human coronaviruses are; a beta coronavirus that causes Middle East Respiratory Syndrome (named MERS-CoV), a beta coronavirus that causes severe acute respiratory syndrome (named SARS-CoV, or SARS-CoV-1), a novel coronavirus that causes coronavirus disease 2019 or COVID-19 (named SARS-CoV-2), alpha coronavirus 299E, alpha coronavirus NL63, beta coronavirus OC43, and beta coronavirus HKU1.
The disease or syndrome caused by a SARS-CoV-2 infection is also referred to as COVID-19.
A SARS-CoV-2 infection can be either asymptomatic or lead to a disease or syndrome related to mild or severe symptoms. The most common symptoms of a disease or syndrome related to a SARS-CoV-2 (also referred to as SARS-CoV-19) infection are fever and cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste. Further symptoms include lack of appetite, loss of weight, stomach pain, conjunctivitis, skin rash, lymphoma, apathy, and somnolence.
Patients with severe symptoms can develop pneumonia. A significant number of patients with pneumonia require passive oxygen therapy. Non-invasive ventilation and high-flow nasal oxygen therapy can be applied in mild and moderate non-hypercapnia pneumonia cases. A DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] lung-saving ventilation strategy must be implemented in severe acute respiratory syndrome or acute respiratory distress syndrome (SARS/ARDS) and mechanically ventilated patients.
While the principal complication of coronavirus disease 2019 (COVID-19) is respiratory failure, a considerable number of patients have been reported with neurological symptoms affecting both the peripheral and central nervous systems (Niazkar, Zibaee et al. 2020 Neurol Sci 41(7): 1667-1671; Nordvig, Fong et al. 2021, Neurol Clin Pract 11(2): e135-e146). The hematogenic pathway, retro-/antero-grade transport along peripheral nerves as well as rare direct invasion, are considered as potential neuroinvasion mechanisms of neurotropic virus including SARS- CoV-2 (Barrantes 2021 Brain Behav Immun Health 14: 100251; Tavcar, Potokar et al. 2021, Front Cell Neurosci 15: 662578). Severe cases of SARS-CoV-2 often exhibit disproportionate and abnormal inflammatory responses, including systemic upregulation of cytokines, chemokines, and pro-inflammatory cues (Najjar, Najjar et al. 2020, J Neuroinflammation 17(1): 231). Such systemic hyper-inflammation could impair the neurovascular endothelial function, damage the blood brain barrier ultimately activating CNS immune system and contributing to CNS complications (Amruta, Chastain et al., 2021, Cytokine Growth Factor Rev 58: 1-15).
Despite the attention that the COVID-19 pandemic has recently taken, several other viruses are associated with major brain disorders like Alzheimer’s, Parkinson’s and multiple sclerosis’ disease. The diseases or syndromes related to virus infections further include a wide range of diseases or syndromes such as inflammatory diseases and are a major burden for society.
Therefore, there is a need to improve the treatment and/or prevention of diseases or syndromes related to viruses.
The above technical problem is solved by the aspects disclosed herein and as defined in the claims. 2 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] SUMMARY OF THE INVENTION The present invention provides a composition for use in the treatment and/or prevention of disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection in a subject in need thereof, the composition comprising a therapeutically effective amount of an Alpha1-Antitrypsin protein, a variant, an isoform and/or a fragment thereof. The alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof can be a plasma-extracted AAT, a variant, an isoform and/or a fragment thereof, in particular a human plasma-extracted AAT, a variant, an isoform and/or a fragment thereof; or a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof, preferably the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof. The virus infection such as the coronavirus infection is preferably a SARS-CoV-2 infection. The subject in need of a treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection may have at least i) a lower level of endogenous alpha-antitrypsin (AAT), ii) a higher level of at least one spike protein priming protease, iii) a higher level of an angiotensin converting enzyme 2 (ACE2) receptor, and/or iv) a higher level of interferon- gamma (IFN-γ) compared to at least one subject who is asymptomatic or has mild symptoms during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection.
The invention also relates to a method for determining the susceptibility of a subject of interest for treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection using the composition for use of the present invention.
The invention further provides a method for determining the therapeutically effective amount of alpha1-antitrypsin (AAT) for an effective treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection using the composition for use of the present invention.
Also provided is a method of treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection in 3 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] a subject in need thereof, the method comprising administering a therapeutically effective amount of an Alpha1-Antitrypsin protein, a variant, an isoform and/or a fragment thereof. The alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof can be a plasma-extracted AAT, a variant, an isoform and/or a fragment thereof, in particular a human plasma-extracted AAT, a variant, an isoform and/or a fragment thereof; or a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof, preferably the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof.
Accordingly, the invention relates to, inter alia, the following aspects: 1. A composition for use in the treatment and/or prevention of a disease or syndrome related to a virus infection in a subject in need thereof, the composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof. 2. The composition for use according to aspect 1, wherein the subject in need thereof has at least one selected from the group consisting of: 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection or during a virus infection compared to at least one subject during a virus infection, which is asymptomatic or has mild symptoms 2. a higher level of at least one spike protein priming protease prior to a virus infection or during a virus infection compared to at least one subject during a virus infection, which is asymptomatic or has mild symptoms, 3. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection or during a virus infection compared to at least one subject during a virus infection, which is asymptomatic or has mild symptoms, and 4. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection or during a virus infection compared to at least one subject during a virus infection, which is asymptomatic or has mild symptoms. 4 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 3. The composition for use according to aspect 2, wherein the lower level of endogenous AAT prior to a virus infection or during a virus infection is caused by AAT-deficiency. 4. The composition for use according to aspect 2 or 3, wherein the spike protein priming protease is at least one selected from the group consisting of transmembrane protease serine subtype 2 (TMPRSS2), transmembrane protease subtype 6 (TMPRSS6), cathepsin L, cathepsin B, proprotein convertase 1 (PC1), trypsin, elastase, neutrophil elastase, matriptase and furin, preferably cathepsin L and furin. 5. The composition for use according to any of the aspects 2 to 4, wherein the higher level of at least one spike protein priming protease is caused by age and/or a genetic predisposition. 6. The composition for use according to any of the aspects 2 to 5, wherein the higher level of ACE2 receptor is caused by at least one selected from the group of an infection, inflammation, age and/or a genetic predisposition. 7. The composition for use according to any of the aspects 2 to 6, wherein the higher level of IFN-γ is caused by at least one selected from the group of an infection, inflammation, age and a genetic predisposition. 8. The composition for use according to any of the aspects 2 to 7, wherein the subject in need thereof has i) a lower level of endogenous AAT, and ii) a higher level of at least one spike protein priming protease. 9. The composition for use according to any of the aspects 2 to 8, wherein the subject in need thereof has i) a lower level of endogenous AAT and iii) a higher level of ACE2 receptor.
. The composition for use according to any of the aspects 2 to 9, wherein the subject in need thereof has i) a lower level of endogenous AAT and DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] iv) a higher level of IFN-γ. 11. The composition for use according to aspect 10, wherein the higher level of IFN-γ is caused by at least one disease or condition selected from the group consisting of AAT- deficiency, a liver disease such as a non-alcoholic fatty liver disease, diabetes, obesity and/or a cardiovascular condition. 12. The composition for use according to any of the aspects 2 to 11, wherein the subject in need thereof has i) a lower level of endogenous AAT, ii) a higher level of at least one spike protein priming protease, and iii) a higher level of ACE2 receptor and/or iv) a higher level of IFN-γ. 13. The composition for use according to any one of the preceding aspects, wherein the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is human plasma-extracted. 14. The composition for use according to any one of the aspects 1 to 12, wherein the alpha1- antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is recombinant alpha1-antitrypsin (rhAAT), a variant, an isoform and/or a fragment thereof.
. The composition for use according to aspect 14, wherein the alpha1-antitrypsin protein is as set forth in SEQ ID NO: 1. 16. The composition for use according to aspect 14, wherein the alpha1-antitrypsin fragment is a C-terminal sequence fragment, or any combination thereof. 17. The composition for use according to aspect 14, wherein the alpha1-antitrypsin variant is selected from the group comprising short cyclic peptides derived from the C-terminal sequence as set forth in SEQ ID NO: 2. 18. The composition for use according to aspect 17, wherein the short cyclic peptides derived from the C-terminal sequence of Alpha1-Antitrypsin is selected from the group 6 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] comprising Cyclo-(CPFVFLM)-SH, Cyclo-(CPFVFLE)-SH, Cyclo-(CPFVFLR)-SH, and Cyclo-(CPEVFLM)-SH, or any combination thereof. 19. The composition for use according to any of the previous aspects, wherein the composition further comprises a pharmaceutically acceptable excipient or carrier.
. The composition for use according to any of the previous aspects, wherein the composition further comprises a nucleoside analog, a protease inhibitor, an immune- suppressor (e.g. sarilumab or tocilizumab), an antibiotic, an antibody directed against structural components of the virus, or fragment thereof (e.g. passive immunotherapy), interferon beta (e.g. interferon beta-1a), and/or a vaccine. 21. The composition for use according to any one of the preceding aspects wherein said composition is administered by intravenous injection, intravenous infusion, infusion with a dosator pump, inhalation nasal-spray, eye-drops, skin-patches, slow release formulations, ex vivo gene therapy or ex vivo cell-therapy, preferably by intravenous injection. 22. A method for determining the susceptibility of a subject of interest for treatment and/or prevention of a disease or syndrome related to a virus infection using a composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof as defined in any of aspects 1 to 21, comprising the steps of: a) determining the level of at least one of the group comprising endogenous alpha1- antitrypsin, at least one spike protein priming protease, ACE2 receptor and interferon-gamma in the subject of interest prior to a virus infection or during a virus infection, b) determining the level of at least one of the group comprising endogenous alpha1- antitrypsin, at least one spike protein priming protease, ACE2 receptor and interferon-gamma in at least one reference subject during a virus infection, wherein the reference subject is asymptomatic or has mild symptoms, c) comparing the level of interest determined in step a) to the reference level determined in step b), 7 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] wherein the subject of interest is more susceptible for treatment and/or prevention of a disease or syndrome related to a virus infection if the subject of interest has at least one selected from the group consisting of: 1. a lower level of interest of endogenous alpha-antitrypsin (AAT) compared to the reference level of endogenous AAT, 2. a higher level of interest of at least one spike protein priming protease compared to the reference level of at least one spike protein priming protease, 3. a higher level of interest of angiotensin converting enzyme 2 (ACE2 receptor) compared to the reference level of the ACE2 receptor, and 4. a higher level of interest of interferon-gamma (IFN-γ) compared to the reference level of IFN-γ. 23. A method for determining the therapeutically effective amount of alpha1-antitrypsin (AAT and/or rhAAT) for an effective treatment and/or prevention of a disease or syndrome related to a virus infection using the composition according to any of the aspects 1 to 21 comprising the steps of: a) determining the level of endogenous alpha1-antitrypsin in a subject of interest prior to a virus infection or during a virus infection, b) determining the amount of AAT in the composition, which is required to achieve a level of AAT in the subject of at least 10 µM, preferably at least 20 µM, more preferably at least 50 µM, even more preferably at least 100 µM, and most preferably at least 200 µM. 24. The composition for use according to any one of the aspects 1 to 21, or the method according to aspect 22 and 23, wherein the virus is a coronavirus.
. The composition for use according to aspect 24, or the method according to aspect 24, wherein the virus is a SARS-CoV-2. 26. The composition for use according to any one of the aspects 1 to 25, or the method according to aspects 22 to 25, wherein the disease or syndrome is a respiratory syndrome or a severe acute respiratory syndrome. 8 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 27. The composition for use according to any one of the aspects 1 to 25, or the method according to aspects 22 to 25, wherein the disease or syndrome is an inflammatory disease or syndrome of the nervous system. 28. The composition for use according to any one of the aspects 1 to 27, or the method according to aspect 27, wherein the inflammatory disease or syndrome of the nervous system is a disease or syndrome selected from the group of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease.
DESCRIPTION OF THE INVENTION Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The publications and applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
In the case of conflict, the present specification, including definitions, will control. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention.
The term "comprise/comprising" is generally used in the sense of include/including, that is to say permitting the presence of one or more features or components.
As used in the specification and claims, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise.
As used herein, "at least one" means "one or more", "two or more", "three or more", etc. 9 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] As used herein the terms "subject"/"subject in need thereof", or "patient"/"patient in need thereof " are well-recognized in the art, and, are used interchangeably herein to refer to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human. In some cases, the subject is a subject in need of treatment or a subject with a disease or disorder. However, in other aspects, the subject can be a normal subject. The term does not denote a particular age or sex. Thus, adult, child and newborn subjects, whether male or female, are intended to be covered. Preferably, the subject is a human. Most preferably a human suffering from a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection.
As used herein, the terms "peptide", "protein", "polypeptide", "polypeptidic" and "peptidic" are used interchangeably to designate a series of amino acid residues connected to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.
The terms "nucleic acid", "polynucleotide," and "oligonucleotide" are used interchangeably and refer to any kind of deoxyribonucleotide (e.g. DNA, cDNA, …) or ribonucleotide (e.g. RNA, mRNA, …) polymer or a combination of deoxyribonucleotide and ribonucleotide (e.g.
DNA/RNA) polymer, in linear or circular conformation, and in either single - or double - stranded form. These terms are not to be construed as limiting with respect to the length of a polymer and can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g. phosphorothioate backbones).
In general, an analogue of a particular nucleotide has the same base-pairing specificity; i.e., an analogue of A will base-pair with T.
The term "vector", as used herein, refers to a viral vector or to a nucleic acid (DNA or RNA) molecule such as a plasmid or other vehicle, which contains one or more heterologous nucleic acid sequence(s) of the invention and, preferably, is designed for transfer between different host cells. The terms "expression vector", "gene delivery vector" and "gene therapy vector" refer to any vector that is effective to incorporate and express one or more nucleic acid(s) of the invention, in a cell, preferably under the regulation of a promoter. A cloning or expression vector may comprise additional elements, for example, regulatory and/or post-transcriptional regulatory elements in addition to a promoter.
DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] The term "about," particularly in reference to a given quantity, is meant to encompass deviations of plus or minus ten (10) percent, preferably 5 percent, even more preferably 2 percent and most preferably 1 percent.
The present invention relates to a composition for use in the treatment and/or prevention of disease or syndrome related to any virus infection in a subject in need thereof, the composition comprising a therapeutically effective amount of an Alpha1-Antitrypsin protein, a variant, an isoform and/or a fragment thereof.
The alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof can be a plasma-extracted AAT, a variant, an isoform and/or a fragment thereof, in particular a human plasma-extracted AAT, a variant, an isoform and/or a fragment thereof; or a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof, preferably the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof. The virus infection can be due to a DNA virus (double or single stranded), an RNA virus (single or double stranded, whether positive of negative), a reverse transcribing virus or any emerging virus, whether enveloped or non-enveloped.
In some aspects of the invention, the composition is used in the treatment and/or prevention of disease or syndrome related to a respiratory virus infection in a subject in need thereof. In some aspects, the respiratory virus described herein is a virus selected from the group of Rhinovirus, RSV, Parainfluenza, Metapneumovirus, Coronavirus, Enterovirus, Adenovirus, Bocavirus, Polyomavirus, Herpes simplex virus, and Cytomegalovirus.
In some aspects of the invention, the composition is used in the treatment and/or prevention of disease or syndrome related to a DNA virus infection in a subject in need thereof.
In some aspects, the DNA virus described herein is selected from the group consisting of Adenovirus, Rhinovirus, RSV, Influenza virus, Parainfluenza virus, Metapneumovirus, Coronavirus, Enterovirus, Adenovirus, Bocavirus, Polyomavirus, Herpes simplex virus, Cytomegalovirus, Bocavirus, Polyomavirus, and Cytomegalovirus.
In some aspects of the invention, the composition is used in the treatment and/or prevention of disease or syndrome related to an RNA virus infection in a subject in need thereof. The RNA virus may be an enveloped or coated virus or a nonenveloped or naked RNA virus. The RNA virus may be single stranded RNA (ssRNA) virus or a double stranded RNA (dsRNA) virus.
The single stranded RNA virus may be a positive sense ssRNA virus or a negative sense ssRNA virus. 11 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] In some aspects, the RNA virus described herein is selected from the group consisting of Rhinovirus, RSV, Influenza virus, Parainfluenza virus, Metapneumovirus, Coronavirus, Enterovirus Adenovirus, Bocavirus, Polyomavirus, Herpes simplex virus, and Cytomegalovirus.
In some aspects of the invention, the composition is used in the treatment and/or prevention of disease or syndrome related to an Coronavirus infection in a subject in need thereof. In some aspects, the Coronavirus described herein is a Coronavirus from the genus selected from the group of α-CoV, β-CoV, γ-CoV or δ-CoV. In another specific aspect, the Coronavirus described herein is of the genus α-CoV or β-CoV. In some aspects, the Coronavirus described herein is selected from the group consisting of Human coronavirus OC43 (HCoV-OC43), Human coronavirus HKU1 (HCoV- HKU1), Human coronavirus 229E (HCoV-229E), Human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), Middle East respiratory syndrome- related coronavirus (MERS-CoV or "novel coronavirus 2012"), Severe acute respiratory syndrome coronavirus (SARS-CoV or "SARS-classic"), and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or "novel coronavirus 2019"). Preferably, the virus infection is an RNA virus infection, most preferably a coronavirus infection due to a coronavirus selected from the non-limiting group comprising MERS-CoV, SARS-CoV and SARS-CoV-2. Most preferably the virus infection is a SARS-CoV-2 infection.
It is to be understood that the invention includes all disease or syndrome related a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection. The disease or syndrome related to a SARS-CoV-2 - infection is also referred to as COVID-19. In one aspect, the disease or syndrome related a virus infection is an inflammation, e.g. of blood vessels throughout the body (e.g. Kawasaki disease), an immune disease (e.g. Grave's disease) and/or a respiratory syndrome, in particular a severe acute respiratory syndrome. The disease or syndrome can be related a virus infection in that the virus infection is associated with the disease or syndrome, prior to the disease or syndrome, contributes to the disease or syndrome and/or causes the disease or syndrome. For example the virus infection may induce inflammation that directly or indirectly induces a disease or syndrome. The inflammation related to the virus infection may be acute or chronic inflammation. The inflammation related to the virus infection may subsequently persist systemically and/or in a specific organ e.g. the brain and/or induce lasting damages. In some aspects of the invention, the composition is used in the treatment and/or prevention of an inflammatory disease or syndrome of the nervous system related to a virus infection in a subject in need thereof. 12 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] The term "inflammatory disease or syndrome of the nervous system", as used herein, refers to a disease, a syndrome and/or a condition that is characterized by increased inflammation in the nervous system compared to a healthy reference subject. The disease or syndrome described herein including disease or syndrome of the nervous system is related to a virus. Inflammation is characterized by a dysregulation of inflammation markers and/or increased immune cell infiltration, activation, proliferation, and/or differentiation in the blood and/or the brain. An inflammation marker is a marker that is indicative for inflammation in a subject. In certain aspects the inflammatory marker described herein is a marker selected from the group of CRP, erythrocyte sedimentation rate (ESR), and procalcitonin (PCT), Interleukin (e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL- 31, IL-33, IL-32, IL-33, IL-35 or IL-36) Tumor necrosis factor (e.g., TNF alpha, TNF beta) , Interferon (e.g., interferon gamma) MIP-I, MCP-I, RANTES, other chemokines and/or other cytokines. An inflammatory marker may also be detectable indirectly, e.g., by detection of an inhibitory factor of an inflammatory marker (e.g., binding factor and/or antagonist). In some aspects, the inflammatory marker is measured in cells involved in inflammation, in cells affected by cells involved in inflammation, in the cerebrospinal fluid, and/or in the blood. In some aspects, the inflammation marker is indicative for immune cell infiltration, activation, proliferation and/or differentiation. Detection of the inflammation marker or the ratio of two or more inflammation markers is detected outside the normal range. The normal range of inflammation markers and whether a marker(ratio) has to be below or above a threshold to be indicative for inflammation is known to the person skilled in the art. In some aspects, the gene expression level, the RNA transcript level, the protein expression level, the protein activity level and/or the enzymatic activity level of at least one inflammation marker is detected. In some aspects at least one inflammation marker is detected quantitatively and/or qualitatively to determine the inflammatory disease or syndrome of the nervous system in a subject in need of treatment and/or prevention.
In some aspects, the inflammatory disease or syndrome of the nervous system described herein is characterized by acute inflammation, that is the duration of inflammation symptoms typically takes from about a few minutes (e.g., 2, 5, 10, 15, 30, 45 minutes) to a few days (e.g., 2, 3, 5, 7, 10 or 14 days). Acute inflammation typically occurs as a direct result of a stimulus such as virus infection. In some aspects, the inflammatory disease or syndrome of the nervous system is characterized by chronic inflammation, that is the duration of symptoms of inflammation typically take at least about a few days (e.g., 2, 3, 5, 7, 10 or 14 days) or the symptoms of 13 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] inflammation reoccur at least once (e.g., once or more times, twice or more times or three or more times). In some aspects, the inflammatory disease or syndrome of the nervous system is characterized by chronic low-grade inflammation. Chronic low-grade inflammation can occur in the absence of clinical symptoms.
In certain aspects, the subject in need of treatment and/or prevention has a history of a virus infection. Therefore the subject in need of treatment and/or prevention was infected with the virus at least once. In certain aspects the subject in need of treatment and/or prevention was infected with the virus at least once. In certain aspects the subject in need of treatment and/or prevention was infected with the virus at least once during childhood. In certain aspects the subject in need of treatment and/or prevention was infected with the virus at least once. In certain aspects the subject in need of treatment and/or prevention was infected with the virus at least once during the last 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0.5 year(s). In certain aspects, the virus infection is active (e.g. detectable) at the timepoint of diagnosis of the inflammatory disease or syndrome of the nervous system in the subject in need of treatment and/or prevention.
Methods for detecting virus infections are known to the person skilled in the art. In some aspects, the invention relates to a method for detecting a virus selected from the group of virus isolation, nucleic acid based methods, microscopy based methods, host antibody detection, electron microscopy and host cell phenotype.
In some aspects, the virus infection described herein is detected in a sample such as in a sample selected from the group of nasopharyngeal swab, blood, tissue (e.g. skin), sputum, gargles, bronchial washings, urine, semen, faeces, cerebrospinal fluid, dried blood spots, nasal mucus.
In some aspects, the virus infection described herein is obtained as an information retrieved from the patient history.
Examples for detection of a (previous) SARS-CoV-2 infection include Human IFN-γ SARS- PLUS CoV-2 ELISpot kit (ALP), strips (Mabtech, 3420-4AST-P1-1) or determination of a T-cell response (Zuo, J., Dowell, A.C., Pearce, H. et al., 2021, Nat Immunol).
In some aspects, the inflammatory disease or syndrome of the nervous system described herein is a inflammatory disease or syndrome of the sympathetic nervous system. In some aspects, the inflammatory disease or syndrome of the nervous system described herein is a inflammatory disease or syndrome of the parasympathetic nervous system. In some aspects, the inflammatory disease or syndrome of the nervous system described herein is a inflammatory disease or syndrome of the central nervous system. In some aspects, the inflammatory disease or syndrome 14 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] of the nervous system described herein is a inflammatory disease or syndrome of the peripheral nervous system.
In certain aspects, the inflammatory disease or syndrome of the nervous system related to a virus is selected from the group of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease.
The term "multiple sclerosis", as used herein, refers to a disease or disorder characterized by inflammation, demyelination, oligodendrocyte death, membrane damage and axonal death. In some aspects, the multiple sclerosis described herein refers to relapsing/remitting multiple sclerosis or progressive multiple sclerosis. In some aspects, multiple sclerosis is at least one of the four main multiple sclerosis varieties as defined in an international survey of neurologists (Lublin and Reingold, 1996, Neurology 46(4):907-11), which are namely, relapsing/remitting multiple sclerosis, secondary progressive multiple sclerosis, progressive/relapsing multiple sclerosis, or primary progressive multiple sclerosis (PPMS).
In some aspects, the multiple sclerosis described herein refers to symptoms of multiple sclerosis which comprise vision problems, dizziness, vertigo, sensory dysfunction, weakness, problems with coordination, loss of balance, fatigue, pain, neurocognitive deficits, mental health deficits, bladder dysfunction, bowel dysfunction, sexual dysfunction, heat sensitivity.
The term "Huntington's disease", as used herein, refers to a neurodegenerative disease caused by a tri-nucleotide repeat expansion (e.g., CAG, which is translated into a poly-Glutamine, or PolyQ, tract) in the HTT gene that results in production of pathogenic mutant huntingtin protein (HTT, or mHTT). In some aspects, mutant huntingtin protein accelerates the rate of neuronal cell death in certain regions of the brain. In some aspects, the Huntington's disease described herein refers to symptoms of Huntington's disease which comprise impaired motorfunction, cognitive impairment, depression, anxiety, movement disturbances, chorea, rigidity, muscle contracture (dystonia), slow eye movements or abnormal eye movements, impaired gait, altered posture, impaired balance, unintended weight loss, sleep rhythm disturbances, circadian rhythm disturbances and autonomic nervous system dysfunction.
The term "amyotrophic lateral sclerosis", as used herein, refers to a progressive neurodegenerative disease that affects upper motor neurons (motor neurons in the brain) and/or lower motor neurons (motor neurons in the spinal cord) and results in motor neuron death. In some aspects, amyotrophic lateral sclerosis includes all of the classifications of amyotrophic DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] lateral sclerosis known in the art, including, but not limited to classical amyotrophic lateral sclerosis (typically affecting both lower and upper motor neurons), Primary Lateral Sclerosis (PLS, typically affecting only the upper motor neurons), Progressive Bulbar Palsy (PBP or Bulbar Onset, a version of amyotrophic lateral sclerosis that typically begins with difficulties swallowing, chewing and speaking), Progressive Muscular Atrophy (PMA, typically affecting only the lower motor neurons) and familial amyotrophic lateral sclerosis (a genetic version of amyotrophic lateral sclerosis).
In some aspects, the term "amyotrophic lateral sclerosis" refers to symptoms of amyotrophic lateral sclerosis, which include, without limitation, progressive weakness, atrophy, fasciculation, hyperreflexia, dysarthria, dysphagia and/or paralysis of respiratory function.
The term "Alzheimer’s disease" (AD), as used herein, refers to mental deterioration associated with a specific degenerative brain disease that is characterized by senile plaques, neuritic tangles and progressive neuronal loss which manifests clinically in progressive memory deficits, confusion, behavioral problems, inability to care for oneself and/or gradual physical deterioration.
In some aspects, subjects suffering Alzheimer’s disease are identified using the NINCDS- ADRDA (National Institute of Neurological and Communicative Disorders and the Alzheimer’s Disease and Related Disorders Association) criteria: 1) Clinical Dementia Rating (CDR) = 1; Mini Mental State Examination (MMSE) between 16 and 24 points and Medial temporal atrophy (determined by Magnetic Resonance Imaging, MRI) >3 points in Scheltens scale. In some aspects, the term Alzheimer’s disease includes all the stages of the disease, including the following stages defined by NINCDS-ADRDA Alzheimer’s Criteria for diagnosis in 1984. 2) Definite Alzheimer’s disease: The patient meets the criteria for probable Alzheimer’s disease and has histopathologic evidence of AD via autopsy or biopsy.
Probable or prodromal Alzheimer’s disease: Dementia has been established by clinical and neuropsychological examination. Cognitive impairments also have to be progressive and be present in two or more areas of cognition. The onset of the deficits has been between the ages of 40 and 90 years and finally there must be an absence of other diseases capable of producing a dementia syndrome. 3) Possible or non-prodromal Alzheimer’s disease: There is a dementia syndrome with an atypical onset, presentation; and without a known etiology; but no co-morbid diseases capable of producing dementia are believed to be in the origin of it. In some aspects, the term Alzheimer’s disease refers one stage of Alzheimer’s disease. In some aspects, the term 16 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Alzheimer’s disease refers to two stages of Alzheimer’s disease. In some aspects, the term "Alzheimer’s disease" refers to symptoms of Alzheimer’s disease, which include without limitation, loss of memory, confusion, difficulty thinking, changes in language, changes in behavior, and/or changes in personality.
The term "Parkinson’s disease", as used herein, refers to a neurological syndrome characterized by a dopamine deficiency, resulting from degenerative, vascular, or inflammatory changes in the basal ganglia of the substantia nigra. Symptoms of Parkinson’s disease include, without limitation, the following: rest tremor, cogwheel rigidity, bradykinesia, postural reflex impairment, good response to 1-dopa treatment, the absence of prominent oculomotor palsy, cerebellar or pyramidal signs, amyotrophy, dyspraxia, and/or dysphasia. In a specific aspect, the present invention is utilized for the treatment of a dopaminergic dysfunction-related syndrome. In some aspects, Parkinson’s disease includes any stage of Parkinson’s disease. In some aspects, the term Parkinson’s disease includes the early stage of Parkinson's disease, which refers broadly to the first stages in Parkinson's disease, wherein a person suffering from the disease exhibits mild symptoms that are not disabling, such as an episodic tremor of a single limb (e.g., the hand), and which affect only one side of the body.
In some aspects, the term Parkinson’s disease includes the advanced stage of Parkinson's disease, which refers to a more progressive stage in Parkinson's disease, wherein a person suffering from the disease exhibits symptoms which are typically severe and which may lead to some disability (e.g., tremors encompassing both sides of the body, balance problems, etc.).
Symptoms associated with advanced-stage Parkinson's disease may vary significantly in individuals and may take several years to manifest after the initial appearance of the disease.
In some apects, the term "Parkinson’s disease" refers to symptoms of Parkinson’s disease, which include without limitation, tremors (e.g., tremor which is most pronounced during rest), shaking (e.g. trembling of hands, arms, legs, jaw and face), muscular rigidity, lack of postural reflexes, slowing of the voluntary movements, retropulsion, mask-like facial expression, stooped posture, poor balance, poor coordination, bradykinesia, postural instability, and/or gait abnormalities. 17 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Examples of established links of inflammatory disease or syndrome of the nervous system and virus infections: Brain disorder Virus involved Virus family Reference Parkinson’s Disease Hepatitis C Flaviviridae Tsai, Liou et al. 2016 (PD) Neurology 86(9): 840-846 H5N1 Orthomyxoviridae Jang, Boltz et al. 2012 J Neurosci 32(5): 1545-1559 SARS-CoV-2 Coronaviridae (Sulzer, Antonini et al. 2020 NPJ Parkinsons Dis 6: 18.) HIV Retroviridae Tse, Cersosimo et al. 2004 Parkinsonism Relat Disord (6): 323-334.
Alzheimer’s Disease Herpes Herpesviridae Abbott 2020 Nature (AD) 587(7832): 22-25.
Multiple Sclerosis Epstein-Barr Herpesviridae Soldan and Lieberman, 2020, (MS) Drug Discov Today Dis Models 32(Pt A): 35-52 Herpes Herpesviridae Virtanen and Jacobson, 2012, CNS Neurol Disord Drug Targets 11(5): 528-544.
The disease or syndrome is preferably related to a coronavirus infection, and more preferably the disease or syndrome is related to a SARS-CoV-2 infection. The disease of syndrome related to a SARS-CoV-2 disease or syndrome is preferably at least one selected form the group consisting of fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste, lack of appetite, loss of weight, stomach pain, conjunctivits, skin rash, lymphoma, apathy, and somnolence, preferably fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste. 18 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] The present invention relates to a composition for use in the treatment and/or prevention of disease or syndrome related to a virus infection, preferably a coronavirus infection in a subject in need thereof, the composition comprising a therapeutically effective amount of an Alpha1- Antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof. The coronavirus is preferably SARS-CoV-2.
The inventor(s) found that AAT and rhAAT inhibits viral entry of several viruses (see Figure 11, 21, 22) and reduces inflammation, in particular in microglia of the nervous system (Figure 19, 20). Furthermore, SH-SY5Y cells that are of neuronal origin and are frequently used to study neurodegenerative disease, including Parkinsons’s disease (Xicoy, H., Wieringa, B. & Martens, G.J. The SH-SY5Y cell line in Parkinson’s disease research: a systematic review. Mol Neurodegeneration 12, 10, 2017) display a realtively high copy number of spike protein priming proteases mRNA, namely trypsin and cathepsin B (Figure 15e). Coupled with a relatively high level of ACE2 expression in SH-SY5Y (Figure 3a), these neural tissue (Bielarz V, Willemart K, Avalosse N, et al. Susceptibility of neuroblastoma and glioblastoma cell lines to SARS- CoV-2 infection. Brain Res. 2021 May 1) and cells of similar origin, becomesusceptible to SARS-CoV-2 viral infection..
Various strategies can be used to deliver the composition for use of the invention to the nervous system, including the brain and to pass the blood brain barrier (Salameh, T. S., & Banks, W.
A., 2014, Advances in pharmacology, 71, 277-299; Tashima, T., 2020, Receptor-Mediated Transcytosis. Chemical and Pharmaceutical Bulletin, 68(4), 316-32; Pardridge, W. M., 2020, Frontiers in aging neuroscience, 11, 373; Upadhyay, R. K., 2014, BioMed research international).
In some aspects, the composition for use of the invention is fused to a blood-brain barrier enhancing protein. In some aspects the blood-brain barrier enhancing protein described herein is at least one full protein, variant, isoform and/or fragment of the protein selected from the group of transferrin, insulin, insulin-like growth factor, low density lipoprotein.
Trojan horse strategies may also be used (see e.g. Pardridge, W.M., 2017, BioDrugs 31, 503– 519). In some aspects, the composition for use of the invention is linked to an antibody or a fragment thereof that binds to an endogenous BBB receptor transporter, such as the insulin receptor or transferrin receptor.
The composition for use of the invention may also be altered to increase lipophilicity and subsequently improve BBB crossing properties (see e.g. Upadhyay, R. K., 2014,. BioMed 19 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] research international, Article ID 869269, 37 pages). In some aspects, the composition for use of the invention comprises modifications that increase the lipophilicity. In some aspects the modifications that increase the lipophilicity described herein comprise the addition of at least one hypdrophilic peptide, replacement of sequence parts with at least one hypdrophilic peptide, the addition of lipid moieties, and/or replacement of non-lipid moieties with lipid moieties.
Accordingly, the invention is at least in part based on the broad effect of AAT on diseases or syndromes related to virus infections.
Particular subjects can be particularly suitableto treatment and/or prevention with AAT and/or rhAAT protein.
Therefore, the present invention also relates a composition for use in the treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection in a subject in need thereof, the composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof, wherein the subject in need thereof has at least one altered level selected from i) endogenous alpha-antitrypsin (AAT), at least one spike protein priming protease, angiotensin converting enzyme 2 (ACE2 receptor) and interferon- gamma (IFN-γ) compared to at least one reference subject. The alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof can be a plasma-extracted AAT, a variant, an isoform and/or a fragment thereof, in particular a human plasma-extracted AAT, a variant, an isoform and/or a fragment thereof; or a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof, preferably the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is a recombinant alpha1- antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof.
The "subject in need thereof" is also referred to as a subject of interest. The subject in need thereof is a subject can be a subject during or with a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection (i.e. an infected subject) having a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection. An infected subject can require treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection. The treatment with AAT and/or rhAAT can inhibit or DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] reduce the entry of the virus infection, preferably the coronavirus infection, more preferably the SARS-CoV-2 virus into the cells by inhibiting the spike protein priming protease, reduce the propagation of the virus infection, preferably the coronavirus infection, more preferably the SARS-CoV-2 virus in the body and/or reduce inflammation as a response to the virus infection, preferably the coronavirus infection, more preferably the SARS-CoV-2 infection. A subject in need of a treatment and/or prevention can have a respiratory syndrome, more preferably an acute respiratory syndrome, even more preferably a severe acute respiratory syndrome. The subject in need of a treatment and/or prevention may have at least one symptom selected from the group of consisting of fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste, lack of appetite, loss of weight, stomach pain, conjunctivits, skin rash, lymphoma, apathy, and somnolence, preferably from the group consisting of fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste. A subject in need of a treatment and/or prevention may require intensive care and/or artificial ventilation. A subject in need of a treatment and/or prevention can be defined by one of the above definitions or any combination thereof.
A subject in need thereof can also be a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is particularly susceptible to delevop a disease or syndrome after a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection. Such a subject may require prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection prior to infection.
The at least one reference subject can be a group of reference subjects. Preferably, the reference (reference) subject(s) is/are a subjects with or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection (i.e. an infected subject) which is/are asymptomatic or has/have mild symptoms, more preferably subject(s) is/are subjects with or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is/are asymptomatic. 21 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Asymptomatic according to the present invention means that the (reference) subject has no symptoms, preferably has no symptoms selected from the group of consisting of no fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste, lack of appetite, loss of weight, stomach pain, conjunctivits, skin rash, lymphoma, apathy, and somnolence, more preferably has no fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste. A asymptomatic (reference) subject preferably have no respiratory syndrome, more preferably no acute respiratory syndrome, even more preferably no severe acute respiratory syndrome. A asymptomatic (reference) subject does not require intensive care and/or artificial ventilation. A asymptomatic (reference) subject can be defined by one of the above definitions or any combination thereof.
A (reference) subject with mild symptoms according to the present invention preferably have no respiratory syndrome, more preferably no acute respiratory syndrome, even more preferably no severe acute respiratory syndrome. A (reference) subject with mild symptoms preferably does not require intensive care and/or artificial ventilation. A (reference) subject with mild symptoms can have at least one symptom selected from the group consisting of fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste, lack of appetite, loss of weight, stomach pain, conjunctivits, skin rash, lymphoma, apathy, and somnolence, more preferably has no fever, cough, fatigue, difficulty breathing, chills, joint or muscle pain, expectoration, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting, diarrhea, sinus pain, stuffy nose, reduced or altered sense of smell or taste, wherein the (reference) subject with mild symptoms does not require intensive care and/or artificial ventilation. A (reference) subject with mild symptoms can be defined by one of the above definitions or any combination thereof.
A reference subject can be a child, in particular a child having an age of less than 10 years, preferably less than 5 years. A reference subject can have an age of between 1 to 10 years, preferably 2 to 5 years. 22 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] A (reference) subject during or with a virus infection, particularly a coronavirus infection, more particularly a SARS-CoV-2 infection is a subject, which is preferably a (reference) subject infected with a virus, particularly a coronavirus, more particularly SARS-CoV-2. An infected (reference) subject means that the virus, particularly the coronavirus, more particularly the SARS-CoV-2 virus has entered the cells of the body of the (reference) subject, in is preferably proliferating in the cells of the body of the (reference) subject.
After infection with a virus, particularly a coronavirus, more particularly SARS-CoV-2, the interferon-gamma levels in the infected subject increase. The increased interferon-gamma levels in turn lead to an increase in the level of the angiotensin converting enzyme 2 (ACE2 receptor). Increased levels of the angiotensin converting enzyme 2 (ACE2 receptor) stimulate increased activity and priming of the spike protein by proteases. Then, the endogenous levels of AAT decrease in response to the increased activity level(s) of at least one spike protein priming protease. Afterwards, endogenous level of AAT deplete further as AAT binds (and inhibits) active spike protein priming proteases. Subjects having at least one selected from the group of i) a lower level of endogenous alpha-antitrypsin (AAT), ii) a higher level of at least one spike protein priming protease, iii) a higher level of angiotensin converting enzyme 2 (ACE2 receptor) and iv) a higher level of interferon-gamma (IFN-γ) compared to at least one reference subject, are particularly susceptible to develop a disease or syndrome in response to the virus, particularly the coronavirus, more particularly the SARS-CoV-2 infection. Therefore, these subjects of interest are particularly relevant and suited to receive treatment and/or prevention using a composition comprising a therapeutically effective amount of an alpha1- antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof. The alpha1- antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof can be a plasma- extracted AAT, a variant, an isoform and/or a fragment thereof, in particular a human plasma- extracted AAT, a variant, an isoform and/or a fragment thereof; or a recombinant alpha1- antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof, preferably the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is a recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof. Most preferably, the AAT protein is recombinant alpha1-antitrypsin (rhAAT) protein, produced in a Chinese Hamster Ovary (CHO) cell and/or in a Human Embryonic Kidney (HEK) cell. 23 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] The present invention also relates to a composition for use in the treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection in a subject in need thereof, the composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein and/or recombinant alpha1-antitrypsin (rhAAT) protein, a variant, an isoform and/or a fragment thereof, wherein the subject in need thereof has at least one selected from the group consisting of: 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 2. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 3. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 4. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
The at least one subject, which is asymptomatic or has mild symptoms is also referred to as at least one reference subject. The reference subject is defined as described herein. 24 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] The "subject in need thereof "is also referred to as a subject of interest. The in need of a treatment and/or prevention of a disease syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection is defined as described herein.
The levels as defined in i) to iv) can be protein levels and/or mRNA levels, preferably a protein or mRNA level. Protein level(s) are measured using antibody-based assays such as enzyme- linked immunosorbent assay (ELISA), and/or bio-layer interferometry (BLI) based on fiber optic biosensors (ForteBio Octet).
Level of spike protein priming protease can be determined by measuring the activity of the spike protein protease using fluorogenic peptides derived from SARS-CoV-2 spike protein. The method is described in Jaimes et. al (Javier A. Jaimes, Jean K. Millet, Gary R. Whittaker Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site, CELL, iScience 23, 101212, June 26, 2020). Transparent Methods Peptides: Fluorogenic peptides derived from SARS-CoV-2 spike (S) S1/S2 sites composed of the sequences HTVSLLRSTSQ (SEQ ID NO: 11) and TNSPRRARSVA (SEQ ID NO: 12) sequences, respectively, and harboring the (7- methoxycoumarin-4-yl)acetyl/2,4-dinitrophenyl (MCA/DNP) FRET pair were synthesized by Biomatik (Wilmington, DE, USA). Recombinant furin can be purchased from New England Biolabs (Ipswich, MA, USA). Recombinant L-1- Tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin can be obtained from Sigma-Aldrich (St Louis, MO, USA). Recombinant PC1, matriptase, cathepsin B, and cathepsin L can be purchased from R&D Systems (Minneapolis, MN, USA). Fluorogenic peptide assay: For each fluorogenic peptide, a reaction is performed in a 100 μL volume with buffer composed of 100 mM Hepes, 0.5% Triton X-100, 1 mM CaCl2 and 1 mM 2-mercaptoethanol pH 7.5 for furin (diluted to 10 U/mL); 25 mM MES, 5 mM CaCl2, 1% (w/v) Brij-35, pH 6.0 for PC1 (diluted to 2.2 ng/μL); PBS for trypsin (diluted to 8 nM); 50 mM Tris, 50 mM NaCl, 0.01% (v/v) Tween® 20, pH 9.0 for matriptase (diluted to 2.2 ng/μL); 25 mM MES, pH 5.0 for cathepsin B (diluted to 2.2 ng/μL); 50 mM MES, 5 mM DTT, 1 mM EDTA, 0.005% (w/v) Brij- , pH 6.0 for cathepsin L (diluted to 2.2 ng/μL) and with the peptide diluted to 50 μM.
Reactions are performed at 30 °C in triplicates, and fluorescence emission is measured every minute for 45 min using a SpectraMax fluorometer (Molecular Devices, Sunnyvale, CA, USA), with λex 330 nm and λem 390 nm wavelengths setting, enabling tracking of fluorescence intensity over time and calculation of Vmax of reactions. Assays should be performed in triplicates with results representing averages of Vmax from three independent experiments.
DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Level of IFN-γ protein could be measured using a flow cytometry, particle-based immunoassay.
The method can be adopted from Huang et. al., (Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185-194. doi:10.1002/jmv.20255) BD Human Th1/Th2 Cytokine or Chemokine Bead Array (CBA) Kit.
The BD Human Th1/Th2 Cytokine CBA Kit (BD PharMingen, San Diego, CA) to measure IFN-γ levels by flow cytometry in a particle-based immunoassay. This kit allowed simultaneous measurement of six cytokines from 50 ml of patient serum sample. The limits of detection of these immunoassays is 7.1 pg/ml for IFN-γ.
Preferably, the endogenous level of AAT described herein is a protein level. The level of the at least one spike protein protease described herein is preferably mRNA level. The level of the ACE2 receptor described herein is preferably a mRNA level. The level of IFN-γ described herein is preferably a protein level. The protein and/or mRNA levels can be measured in blood, urine or saliva, preferably in blood, more preferably in blood plasma, most preferably in human blood plasma.
Several factors of the entry of viruses, particularly coronaviruses, more particularly the SARS- CoV-2 virus into cells and propagation in cells are already understood, while others are still subject of investigation. Entry of the SARS-CoV-2 virus is mediated by the spike protein, spike protein priming protease(s) and an ACE2 receptor. The SARS-CoV-2 spike protein is also referred to as spike protein S. The spike protein priming protease cleaves the spike protein of SARS-CoV-2 thereby priming the SARS-CoV-2 for entry into the cell. SARS-CoV-2 enters the cell by interaction of the primed spike protein with the ACE receptor. Thus, if at least one or more priming protease(s) is present in the subject of interest, the easier and faster the entry of the SARS-CoV-2 virus into the cells. Also, the more ACE2 receptor(s) is present, the easier and faster the entry of the SARS-CoV-2 into the cells. The infection with SARS-CoV-2 leads to inflammation and thus elevated IFN-γ expression. IFN-γ expression in response to a SARS- CoV-2 infection can in turn lead to an increased expression of the ACE2 receptor. During proliferation of SARS-CoV-2, IFN-γ levels increase further, stimulating the increase in ACE2 interaction with the spike protein and subsequently the priming of the spike protein, AAT levels decrease and upon viral entry into the cells, inflammation increases, which leads to even higher levels of IFN-γ. After infection with SARS-CoV-2, first, the IFN-γ levels increase, second, the 26 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] AAT levels decrease and the levels of cathepsin L increase and/or other spike protein priming (S-priming) proteases increase. See Figure 1.
Therefore, the invention is at least in part based on the discovery, that AAT as well as rhAAT simultaneously reduces viral entry (see e.g. Figure 6, 7, 8, 11, 12, 21, 22) and virus associated inflammation (see e.g. Figure 19, 20), in particularly virus associated inflammation due to high IFN-γ levels. This combined effect is particularly useful in the patient populations described herein.
In certain aspects the invention relates to the composition for use according to the invention, wherein the spike protein priming protease is at least one selected from the group consisting of transmembrane protease serine subtype 2 (TMPRSS2), transmembrane protease subtype 6 (TMPRSS6), cathepsin L, cathepsin B, proprotein convertase 1 (PC1), trypsin, elastase, neutrophil elastase, matriptase and furin.
In certain aspects the invention relates to the composition for use according to the invention, wherein the spike protein priming protease is cathepsin L and/or furin.
AAT is endogenously expressed in the human body. AAT is also referred to as alpha-1- proteinase inhibitor. AAT is capable of inhibiting proteases, specifically spike protein proteases, such as transmembrane protease serine subtype 2 (TMPRSS2), transmembrane protease subtype 6 (TMPRSS6 / matriptase-2), cathepsin L, cathepsin B, proprotein convertase 1 (PC1), trypsin, elastase, neutrophil elastase, matriptase and furin. If the levels of the four players of the present invention (AAT, spike protein priming protease(s), ACE2 receptor and IFN-γ) are altered in an infected subject of interest compared to a reference subject, the infected subject of interest may benefit particularly form a treatment and/or prevention of a diseases or syndrome related with a SARS-CoV-2 infection. Low endogenous AAT levels can lead to a higher susceptibility of a subject of interest to develop a disease or syndrome related to SARS-CoV-2, in particular to develop COVID-19.
In certain aspects the invention relates to the composition for use according to the invention, wherein the lower level of endogenous AAT prior to a virus infection or during a virus infection is caused by AAT-deficiency.
Alpha1-Antitrypsin (hereafter "AAT") is a protein that naturally occurs in the human body and is produced in the liver, preferably in hepatocytes. According to Janciauskiene et. al., 27 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] (Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Köhnlein T, Welte T. The discovery of α1-antitrypsin and its role in health and disease. Respir Med. 2011;105(8):1129-1139. doi:10.1016/j.rmed.2011.02.002) the normal plasma concentration of AAT ranges from 0.9 to 1.75 g/L. Considering a MW of 52,000 (Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988;84(6A):13-31. doi:10.1016/0002- 9343(88)90154-4), this corresponds to 16 to 32 µM normal blood plasma concentrations.
Crystal 1990 (Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease.
Genetic basis and strategies for therapy. J Clin Invest. 1990 May;85(5):1343-52. doi: .1172/JCI114578. PMID: 2185272; PMCID: PMC296579) describes that 11 µM is the threshold level for the clinical manifestation of AAT-deficiency. For most healthy individuals, 2g daily expression of AAT in the liver is enough to reach this critical serum level of 11 µM, the endogenous AAT level is then sufficient to protect the lower respiratory tract from destruction by neutrophil elastase (NE) and inhibiting the progressive destruction of the alveoli, which culminates in emphysema. Crystal 1990 further notes that normal endogenous levels of AAT in healthy individuals vary between 20-53 µM. Endogenous levels of AAT protein in the blood plasma of healthy human subjects prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection range between 5 and 60 µM, preferably between 10 and 40 µM, more preferably between 25 to 30 µM, even more preferably between 16 and 32 µM. Alternatively the Endogenous levels of AAT protein in the blood plasma of healthy human subjects prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection is preferably higher than 30 µM, more preferably higher than 40 µM, most preferably higher than 50 µM. AAT protein can be plasma AAT protein or recombinant AAT (rhAAT) protein. In some aspects, Plasma AAT protein is derived from blood plasma. In some aspects, Recombinant AAT protein is produced recombinantly, for example in HEK cells, CHO cells or E. coli cells. Pharmaceutical companies worldwide derive AAT protein from human blood plasma for the treatment of AAT-deficiency, a hereditary disorder. Plasma derived AAT is approved in the US and the EU, by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively. Preferably, the AAT protein of the invention has the human amino acid sequence, most preferably as set forth in SEQ ID NO: 1 (see Table 1).
As shown in Figure 6a and 6c of the present invention, 10 µM of AAT reduces pseudoviral entry by 20-30% in A549 cells, which overexpress the ACE2 receptor. 28 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] According to Azouz et. al. (Nurit P. Azouz, Andrea M. Klingler and Marc E. Rothenberg, Alpha1-Antitrypsin (AAT) is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2, (bioRxiv preprint online, https://doi.org/10.1101/2020.05.04.077826, posted on May 5, 2020) concentrations of 1-100 µM AAT achieve dose-dependent inhibition of TMPRSS2 proteolytic activity.
As shown in Figure 7 of the present invention, 100 µM of AAT reduces pseudoviral entry by 50-75% in A549 cells, which overexpress the ACE2 receptor only.
As shown in Figure 8 of the present invention, 100 µM of AAT reduces pseudoviral entry by up to 45% only in A549 cells that overexpress both the ACE2 receptor and the spike protein priming protease TMPRSS2.
It is important to note that viral entry is observed independently of TMPRSS2 in both Figure 6 and 7 of the current invention. Demonstrating that priming proteases such as furin and/or cathepsin L are able to replace TMPRSS2, probably among others. In this regard, AAT as well as rhAAT reduces the activity of the proteases cathepsin B, cathepsin L, trypsin, furin, PC1, Matriptase, elastase and neutrophil elastase (Figure 16).
Therefore, the inhibitory effect of AAT as well as rhAAT on viral entry extends beyond the effect of other TMPRSS2 inhibitors (Figure 7, 8, 11, 12, 21, 22), in that AAT as well as rhAAT effectively inhibits several priming proteases (Figure 16) (e.g., proteases that can replace TMPRSS2 function) and subsequent ACE2 mediated viral entry (Figure 7, 8, 11, 12, 21, 22).
Therefore, AAT as well as rhAAT reduces viral entry by reducing priming protease activity, in particular by broadly and efficiently reducing priming protease(s) activity.
Accordingly, the invention is at least in part based on the surprising finding that compositions comprising AAT and/or rhAAT, variants, isoforms and/or fragments thereof, are particularly effective in the treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, in particular in a subject with one or more of the preconditions described herein.
In the present invention, the lower level of endogenous AAT according to i) is preferably a protein level in human blood plasma. The level of endogenous AAT protein in human blood plasma according to i) is preferably less than 200 µM, preferably less than 150 µM, 100 µM, 29 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] less than 90, µM, less than 80 µM, less than 70 µM, less than 60 µM, less than 50 µM, less than 40 µM, less than 30 µM, less than 25 µM, less than 20 µM, less than 15 µM, less than 11 µM or less than 10 µM. More preferably less than 200 µM, less than 100 µM, less than 25 µM, less than 15 µM, or less than 11 µM. A low level of AAT is not sufficient to successfully inhibit the spike protein priming protease(s). A low level of endogenous AAT can therefore promote virus proliferation, in particular coronavirus proliferation, more particularly SARS-CoV-2 proliferation and/or the development of a disease of syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection. A lower level of endogenous AAT prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection can be caused by AAT deficiency, preferably lower level of endogenous AAT prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection is caused by AAT deficiency. The AAT-deficiency is a condition that is inherited in an autosomal codominant pattern. Codominance means that two different versions of the gene may be active (expressed), and both versions contribute to the genetic trait. The most common version (allele) of the SERPINA1 gene, called M, produces normal levels of alpha-1 antitrypsin. Most people in the general population have two copies of the M allele (MM) in each cell. Other versions of the SERPINA1 gene lead to reduced levels of alpha-1 antitrypsin. For example, the S allele produces moderately low levels of this protein, and the Z allele produces very little alpha-1 antitrypsin. Individuals with two copies of the Z allele (ZZ) in each cell are likely to have alpha-1 antitrypsin deficiency. Those with the SZ combination have an increased risk of developing lung diseases (such as emphysema), particularly if they smoke. Worldwide, it is estimated that 161 million people have one copy of the S or Z allele and one copy of the M allele in each cell (MS or MZ). Individuals with an MS (or SS) combination usually produce enough alpha-1 antitrypsin to protect the lungs. People with MZ alleles, however, have a slightly increased risk of impaired lung or liver function.
Subjects with an AAT deficiency in the present invention preferably have ZZ mutation, SZ mutation, MS mutation, MZ mutation or SS mutation of the SERPINA1 gene, preferably a ZZ mutation. The low levels of AAT secretion in the ZZ mutation of the SERPINA1 gene are due to misfolding of AAT and its subsequent accumulation in the endoplasmic reticulum (ER) of hepatocytes (Crystal 1990), resulting in progressive liver disease as the accumulation of misfolded AAT negatively affects hepatocytes’ health leading to their ultimate demise.
A lower level of endogenous AAT during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection can also be caused by the virus infection, the DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] coronavirus infection, or the SARS-CoV-2 infection respectively. That is, the level of endogenous AAT in a reference subject can increase temporarily during the virus infection as healthy hepatocytes attempt to overcompensate for the drop in endogenous AAT levels, while the level of endogenous AAT in a subject with genetic AAT-deficiency is lower due to absence or incomplete virus infection-induced increase (lack of healthy hepatocytes).
A lower level of endogenous AAT may also be caused by a liver disease such as a non-alcoholic fatty liver disease, diabetes mellitus type 1 or 2 (preferably type 1), obesity and cardiovascular conditions. Fatty acid deposit build-up in the liver leads to increased stress (increased IFN-γ), tissue inflammation and subsequent damage to hepatocytes causing lower level of healthy secretion of AAT. As with other types of liver maladies, it is important to note that AAT- deficiency leads to liver disease over time as the accumulation of misfolded AAT in the ER of hepatocytes ultimately causes liver failure.
In the present invention, the spike protein priming protease can be any protease capable of priming the spike protein of a virus, preferably a coronavirus, more preferably SARS-CoV-2.
Preferably, the spike protein priming protease is at least one selected from the group consisting of transmembrane protease serine subtype 2 (TMPRSS2), transmembrane protease subtype 6 (TMPRSS6), cathepsin L, cathepsin B, proprotein convertase 1 (PC1), trypsin, elastase, neutrophil elastase, matriptase and furin, more preferably TMPRSS2, cathepsin L and furin, even more preferably cathepsin L or furin. The spike protein priming protease is furin is also referred to as paired basic amino acid cleaving (PACE) enzyme.
The higher level of the at least one spike protein priming protease, preferably Cathepsin L, described herein is preferably a mRNA level in human blood plasma, or a protein level in human blood plasma. The plasma concentration of Cathepsin L in healthy subjects is 0.2 to 1 ng/mL (i.e. 10 to 50 pM given a molecular weight of about 23-24 kDa; (Kirschke 1977 https://febs.onlinelibrary.wiley.com/doi/10.1111/j.1432-1033.1977.tb11393.x). Moreover, immune cells are known to be a major source of extracellular cysteine cathepsins in inflammation, including in the brain (Hayashi et al., 2013, von Bernhardi et al., 2015, Wendt et al., 2008, Wendt et al., 2007). The level of the at least one spike protein priming protease protein described herein is preferably higher than 0.2, 0.5 or 1 ng/ml in human blood plasma. The level of the at least one spike protein priming protein described herein protease is preferably higher than 10, 20, 30, 40, 50, 75 or 100 pM, preferably higher than 10 or 50 pM, even more preferably higher than 50 pM. In this aspect the at least one spike protein priming protease(s) is preferably 31 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] cathepsin L. In certain aspects, the at least one spike protein priming protease(s) described herein are at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine spike protein priming proteases. In certain aspects, the at least one spike protein priming protease(s) described herein is at least one protease selected from the group consisting of TMPRSS2, cathepsin B, cathepsin L, trypsin, furin, PC1, matriptase, elastase and neutrophil elastase. In certain aspects, the at least one spike protein priming protease(s) described herein is at least one protease selected from the group consisting of TMPRSS2, cathepsin B, cathepsin L, trypsin, furin, PC1 and matriptase.
In certain aspects the invention relates to the composition for use according to the invention, wherein the higher level of at least one spike protein priming protease is caused by age and/or a genetic predisposition.
The higher level of the at least one spike protein priming protease can be caused by age and/or a genetic predisposition. In particular, higher level of cathepsin B and L, preferably of cathepsin B can be caused by age. Higher levels of spike protease protein, in particular cathepsin B and L, more preferably cathepsin B can accumulate in the lysosome. The level of spike protein priming protease is higher in subjects of interest, with an age of more than 50 years, preferably more than 60 years, more preferably more than 70 years, even more preferably more than 80 years, and most preferably more than 90 years. Subjects of Afro-American origin may have a genetic predisposition for higher levels of spike protein priming protease, in particular furin.
As shown in Figure 2(a), HeLa cells differ in relative mRNA rates of furin and Cathepsin L compared to A549 cells. HeLa cells are of Afro-American origin. A549 cells are airway epithelial cells of Caucasian origin. As shown in Figure 2(b), HeLa cells are more susceptible to SARS-CoV-2 entry than A549 cells (Figure 6) and are less reactive to treatment with AAT.
A genetic predisposition can be determined by genetic profiling of individual subjects of interest.
In certain aspects the invention relates to the composition for use according to the invention, wherein the higher level of ACE2 receptor is caused by at least one selected from the group of an infection, inflammation, age and a genetic predisposition.
The higher level of ACE 2 receptor described herein is preferably an mRNA level in human blood plasma. The higher level of the ACE2 receptor can be caused by at least one selected 32 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] from the group of an infection, inflammation (e.g. IFN-γ), age and a genetic predisposition. The infection can be a viral infection and/or a bacterial infection, preferably a viral infection, more preferably a coronavirus infection, even more preferably a SARS or SARS-CoV-2 infection. A further example for infection is Leishmaniasis. As shown in Figure 4 and 5, ACE2 receptor expression is upregulated in response to higher levels of IFN-γ, which levels in turn increase as an immune response to inflammation. The inflammation can be caused, for example, by a bacterial and/or viral infection, cancer, delayed type hypersensitivity; autoimmune diseases (such as autoimmune encephalomyelitis, rheumatoid arthritis, autoimmune insulitis (also referred to as type 1 diabetes mellitus), allograft rejection and graft versus host reaction, nonspecific inflammation and cytokine release. The age is preferably an age of more than 50 years, preferably more than 60 years, more preferably more than 70 years, even more preferably more than 80 years, and most preferably more than 90 years. An example of a genetic predisposition for high levels of IFN-γ is familial Mediterranean fever. A genetic predisposition can be determined by genetic profiling of individual subjects of interest. A higher level of ACE2 receptor described herein can also be present in a tissue selected from the group consisting of lung (Calu3), colon (CaCo2), liver (HEPG2), kidney (HEK-293T), and the brain (SH-SY5Y) as confirmed by qPCR and shown in Figure 3a of the current invention.
In certain aspects the invention relates to the composition for use according to the invention, wherein the higher level of IFN-γ is caused by at least one selected from the group of an infection, inflammation, age and a genetic predisposition.
The higher level of interferon-gamma (IFN-γ) according to iv) is preferably a protein or mRNA level in human blood plasma, more preferably a protein level in human blood plasma. In healthy humans, the IFN-γ level is below or around the limit of detection of the assays, e.g. less than to 50 pg/mL) (Billau 1996; Kimura 2001). IFN-γ is produced almost exclusively by natural killer (NK) cells, CD4+ and some CD8+ lymphocytes. Production of IFN-γ by either NK or T cells requires cooperation of accessory cells, mostly mononuclear phagocytes, which also need to be in some state of activation (Billiau A. Interferon-gamma: biology and role in pathogenesis.
Adv Immunol. 1996;62:61-130. doi:10.1016/s0065-2776(08)60428-9). Thus, inflammatory conditions leading to NK cells activation and T cells activation lead to increased IFN-γ levels.
Inflammation state involving circulating NK or T cells (infection, cancer) are expected to lead to higher plasma levels.
The following Table provides values for plasma levels of IFN-γ in several conditions. 33 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Condition Type of IFN-γ IFN-γ- Reference condition (pg/mL) Control (pg/mL) SARS infection 456 (acute 3.3 Huang et. al., phase) (control) Huang, K.‐J., Su, I.‐J., Theron, M., Wu, Y.‐C., Lai, S.‐K., Liu, 26.6 pM 0.19 pM C.‐C. and Lei, H.‐Y. (2005), An interferon ‐γ‐related cytokine storm in SARS patients. J. Med.
Virol., 75: 185-194. doi:10.1002/jmv.20255 Leishmaniasis infection 118 31 (treated) Hailu et. al., (untreated) 1.8 pM Hailu A, van der Poll T, Berhe N, Kager PA. Elevated plasma 6.9 pM levels of interferon (IFN)- gamma, IFN-γ inducing cytokines, and IFN-γ inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg. 2004;71(5):561-567.
Familial Genetic 19.4 4.8 (attack- Köklü et. al., Mediterranean disorder (acute free) Köklü S, Oztürk MA, Balci M, Yüksel O, Ertenli I, Kiraz S. fever attack) 0.28 pM Interferon-gamma levels in 1.1 pM familial Mediterranean fever. Joint Bone Spine. 2005;72(1):38-40. doi:10.1016/j.jbspin.2004.03.01 1 The level of IFN-γ protein in human blood plasma according to iv) is preferably high than 1, 5, , 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 200, 300, 400 or 500 pg/ml. The higher level of IFN-γ is preferably caused by at least one selected from the group of an infection, inflammation, age and a genetic predisposition, more preferably by inflammation. The infection can be a viral infection and/or a bacterial infection, preferably a viral infection, more preferably a coronavirus infection, even more preferably a SARS or SARS-CoV-2 infection. A further example for infection is Leishmaniasis. The inflammation can be caused, for example, by a bacterial and/or viral infection, cancer, delayed type hypersensitivity; autoimmune diseases (such as autoimmune encephalomyelitis, rheumatoid arthritis, autoimmune insulitis (also referred to as 34 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] type 1 diabetes mellitus), allograft rejection and graft versus host reaction, nonspecific inflammation and cytokine release. The age is preferably an age of more than 50 years, preferably more than 60 years, more preferably more than 70 years, even more preferably more than 80 years, and most preferably more than 90 years. An example of a genetic predisposition for high levels of IFN-γ is familial Mediterranean fever. A genetic predisposition can be determined by genetic profiling of individual subjects of interest.
Accordingly, the invention is at least in part based on the surprising finding that compositions comprising AAT as well as rhAAT, variants, isoforms and/or fragments thereof, reduce both virus proliferation and inflammation, in particular IFN-γ associated inflammation.
In one aspect, "subject in need thereof", i.e. the subject of interest has two selected from the group consisting of: 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms 2. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 3. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 4. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
Thus, the "subject in need thereof" can have 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 2. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
Preferably, in this aspect, the AAT protein level in human blood plasma described herein is lower than 52 µM and the cathepsin L protein level in human blood plasma is higher than 10 pM.
In another aspect, the "subject in need thereof" can have 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 2. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms. 36 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] In yet a further aspect, the "subject in need thereof" can have 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 2. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
In these aspects, 1. and 4. can be at least one disease or condition selected from the group consisting of AAT-deficiency, a liver disease such as a non-alcoholic fatty liver disease, diabetes, obesity and a cardiovascular condition. In some aspects the invention relates to the composition for use according to the invention, wherein the higher level of IFN-γ is caused by at least one disease or condition selected from the group consisting of AAT-deficiency, a liver disease such as a non-alcoholic fatty liver disease, diabetes, obesity and a cardiovascular condition. In some aspects the invention relates to the composition for use according to the invention, wherein the lower level of AAT is caused by at least one disease or condition selected from the group consisting of AAT-deficiency, a liver disease such as a non-alcoholic fatty liver disease, diabetes, obesity and a cardiovascular condition. Diabetes can be diabetes mellitus type 1 or type 2. Liver disease can be acetaminophen-induced liver injury, severe chronic hepatitis, alcoholic liver disease (ALD), encompassing a broad spectrum of phenotypes including simple steatosis, steatohepatitis, liver fibrosis and cirrhosis or even HCC (hepatocellular carcinoma).
Cardiovascular condition can be any condition brought on by a sudden reduction or blockage of blood flow to the heart, cardiac infraction, acute coronary syndrome (ACS), also in patients with acute myocardial infarction, whereby the left ventricular ejection fraction is inversely correlated with AAT concentrations in the serum, suggesting that systolic dysfunction is associated with an inflammatory response. 37 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Preferably, in this aspect, the AAT protein level in human blood plasma described herein is lower than 52 µM and the IFN-γ protein level in human blood plasma described herein is higher than 0.19 pM.
In a further aspect, "subject in need thereof", i.e. the subject of interest has two selected from the group consisting of: 1. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 2. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 3. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
In yet a further aspect, the "subject in need thereof" can have 1. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 38 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 2. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
In yet a further aspect, the "subject in need thereof" can have 1. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 2. a higher level of interferon-gamma (IFN- γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
In yet a further aspect, the "subject in need thereof" can have 1. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 2. a higher level of interferon-gamma (IFN-γ) in a subject pr ior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms. 39 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] In a further aspect, the "subject in need thereof", i.e. the subject of interest has three selected from the group consisting of: 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms 2. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 3. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 4. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
Thus, the "subject in need thereof" can have 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a 40 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 2. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 3. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
In a further aspect, the "subject in need thereof" can have 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 2. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 3. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms. 41 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Preferably, in this aspect, the AAT protein level in human blood plasma described herein is lower than 36 µM, the cathepsin L protein level in human blood plasma described herein is higher than 10 pM, the IFN-γ protein level in human blood plasma described herein is higher than 0.19 mM.
More preferably, in this aspect, the AAT protein level in human blood plasma described herein is lower than 52 µM, the cathepsin L protein level in human blood plasma described herein is higher than 10 pM, the IFN-γ protein level in human blood plasma described herein is higher than 0.19 mM.
In a further aspect, the "subject in need thereof" can have 1. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 2. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 3. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
In a further aspect, the "subject in need thereof", i.e. the subject of interest has 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during 42 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms 2. a higher level of at least one spike protein priming protease prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, 3. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms, and 4. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection compared to at least one subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, which is asymptomatic or has mild symptoms.
AAT protein in the composition for use of the present invention can plasma AAT protein, a variant, an isoform and/or a fragment thereof; or recombinant AAT protein, a variant, an isoform and/or a fragment thereof. Preferably, the AAT protein, a variant, an isoform and/or a fragment thereof is recombinant AAT protein, a variant, an isoform and/or a fragment thereof.
Plasma AAT protein is preferably derived from blood plasma AAT protein, more preferably from human blood plasma (also referred to as human plasma-extracted AAT). In certain aspects, the invention relates to the composition for use according to the invention, wherein the alpha1- antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is recombinant alpha1-antitrypsin (also referred to as rhAAT), a variant, an isoform and/or a fragment thereof.
Recombinant AAT protein is produced recombinantly, for example in CHO cells, HEK cells (HEK293 and/or HEK293T) or E. coli cells. Pharmaceutical companies worldwide derive AAT 43 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] protein from human blood plasma for the treatment of AAT-deficiency, a hereditary disorder.
Plasma derived AAT is FDA and EMA approved. Preferably, the AAT protein of the invention has the human amino acid sequence, most preferably as set forth in SEQ ID NO: 1 (see Table 1). Recombinant AAT protein a variant, an isoform and/or a fragment thereof is preferably free from an Fc-domain and/or histidine-tag (His-tag).
The inventor(s) found that recombinant AAT (rhAAT produced in CHO) binds to an AAT- Antibody with a different affinity (Figure 17) and has a more pronounced biologic effect than a plasma-derived AAT. Particularly, recombinant AAT (rhAAT) inhibits ACE2/Spike protein mediated cell fusion (Figure 14) more effectively than plasma derived AAT and has a different enzymatic inhibition profile (Figure 16).
Accordingly, the invention is at least in part based on the surprising finding that recombinant AAT (rhAAT) produced in CHO cells is particularly effective for use in the treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection.
In certain aspects, the invention relates to the composition for use according to the invention, wherein the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is recombinant alpha1-antitrypsin produced by in human cells (e.g. HEK293 or HEK293T cells, see Example 23).
The inventor(s) found that recombinant AAT produced in human cells, specifically in HEK293 (rhAAT without a His-tag), is particular effective in the reduction of enzymatic activity of Cathepsin L (Figure 16b), Trypsin (Figure 16c), Furin (Figure 16d) and Neutrophil Elastase (Figure 16i) compared to recombinant AAT (rhAAT) produced in CHO cells as well as plasma- derived AAT.
Accordingly, the invention is at least in part based on the surprising finding that recombinant AAT produced in human cells, specifically in HEK293, is particularly effective for use in the treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection.
In certain aspects, the invention relates to the composition for use according to the invention, wherein the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof 44 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] is recombinant alpha1-antitrypsin (rhAAT produced in CHO) having more non-human glycan profile. In certain aspects, the non-human glycan profile described herein is a mammalian-cell- derived glycan profile and/or a glycoengineered glycan profile. Glycoengineering strategies, e.g., used to reduce fucosylation and/or enhance sialylation of glycoproteins are known to the person skilled in the art. In certain aspects, the non-human glycan profile described herein is a CHO-cell-derived glycan profile. CHO cells express a different glycosylation machinery than human cells, which results in different composition of glycans at the surface of recombinant proteins (Figure 24) (Lalonde, M. E., & Durocher, Y., 2017, Journal of biotechnology, 251, 128-140).
In certain aspects, the invention relates to the composition for use according to the invention, wherein the AAT protein, a variant, an isoform and/or a fragment thereof is recombinant AAT produced by pXC-17.4 (GS System, Lonza), a variant, an isoform and/or a fragment thereof.
The inventor(s) found that the recombinant AAT produced by pXC-17.4 (GS System, Lonza) in CHO (Recombinant AAT 1) induces a more pronounced inhibitory effect on the activity of Elastase (Figure 16h) and Neutrophil Elastase (Figure 16i) than plasma-derived alpha1- proteinase inhibitor (Plasma-derived AAT) and recombinant AAT produced by PL136/PL137 (pCGS3, Merck) in CHO (Recombinant AAT 2).
Accordingly, the invention is at least in part based on the surprising finding, that certain forms of recombinant AAT (rhAAT) are particularly effective for use in the treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection.
As used herein, a "fragment" of an AAT protein, peptide or polypeptide of the invention refers to a sequence containing less amino acids in length than the AAT protein, peptide or polypeptide of the invention, in particular less amino acids than the sequence of AAT as set forth in SEQ ID NO:1. The fragment is preferably a functional fragment, e.g. a fragment with the same biological activities as the AAT protein as set forth in SEQ ID NO:1. The functional fragment preferably derived from the AAT protein as set forth in SEQ ID NO:1. Any AAT fragment can be used as long as it exhibits the same properties, i.e. is biologically active, as the native AAT sequence from which it derives. 45 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Preferably, the (functional) fragment shares about 5 consecutive amino-acids, at least about 7 consecutive amino-acids, at least about 15 consecutive amino-acids, at least about 20 consecutive amino-acids, at least about 25 consecutive amino-acids, at least about 20 consecutive amino-acids, at least about 30 consecutive amino-acids, at least about 35 consecutive amino-acids, at least about 40 consecutive amino-acids, at least about 45 consecutive amino-acids, at least about 50 consecutive amino-acids, at least about 55 consecutive amino-acids, at least about 60 consecutive amino-acids, at least about 100 consecutive amino-acids, at least about 150 consecutive amino-acids, at least about 200 consecutive amino-acids, at least about 300 consecutive amino-acids, etc… or more of the native human AAT amino acid sequence as set forth in SEQ ID NO:1. In some aspects, the (functional) fragment described herein, comprises an expression optimized signal protein (e.g.
Example 24) The functional AAT fragment can comprise or consist of a C-terminal fragment of AAT as set forth in SEQ ID NO:2. The C-terminal fragment of SEQ ID NO:2 consist of amino acids 374 to 418 of SEQ ID NO:1.
More preferably, the AAT fragment is a fragment containing less amino acids in length than the C-terminal AAT sequence 374-418 (SEQ ID NO: 2). Alternatively, the AAT fragment consists essentially in SEQ ID NO: 2.
Table 1 SE Q ID NO : MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITP NLAEFAFS 1 LYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEA QIHEGF QELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFG DTEEAKKQ 46 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] INDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDF HVDQVTTV KVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENEL THDIITKFL ENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKL SKAVHKA VLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVV NPTQK MFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK 2 Cyclo-(CPFVFLM)-SH 3 Cyclo-(CPFVFLE)-SH 4 Cyclo-(CPFVFLR)-SH 5 Cyclo-(CPEVFLM)-SH 6 The term "variant" refers to a protein, peptide or polypeptide having an amino acid sequence that differ to some extent from the AAT native sequence peptide, that is an amino acid sequence that vary from the AAT native sequence by amino acid substitutions, whereby one or more amino acids are substituted by another with same characteristics and conformational roles.
Preferably, a variant of the present invention is at least 99%, 98%, 97%, 96%, 95%, 90% or 85% homologous to amino acids of SEQ ID NO: 1 or SEQ ID NO:2. A variant can also have at least 99%, 98%, 97%, 96%, 95%, 90% or 85% sequence identity to amino acids of SEQ ID NO:1 or SEQ ID NO:2. The amino acid sequence variants can have substitutions, deletions, and/or insertions at certain positions within the amino acid sequence of the native amino acid sequence, e.g. at the N- or C-terminal sequence or within the amino acid sequence. Substitutions can also be conservative, in this case, the conservative amino acid substitutions are herein defined as exchanges within one of the following five groups: I. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, Gly II. Polar, positively charged residues: His, Arg, Lys III. Polar, negatively charged residues: and their amides: Asp, Asn, Glu, Gln IV. Large, aromatic residues: Phe, Tyr, Trp V. Large, aliphatic, nonpolar residues: Met, Leu, Ile, Val, Cys. 47 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] "Homology" refers to the percent identity between two polynucleotide or two polypeptide moieties. Two nucleic acid, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 50% sequence identity, preferably at least about 75% sequence identity, more preferably at least about 80% or at least about 85% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules. As used herein, substantially homologous also refers to sequences showing complete identity to the specified sequence.
In general, "identity" refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100.
Alternatively, homology can be determined by readily available computer programs or by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single stranded specific nuclease(s), and size determination of the digested fragments. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art.
In some aspects, the invention relates to the composition for use according to the invention, wherein the alpha1-antitrypsin fragment is a C-terminal sequence fragment, or any combination thereof.
The peptidic variants may be linear peptides or cyclic peptides and may be selected from the group comprising short cyclic peptides derived from the C-terminal sequence as set forth in SEQ ID No. 2. Preferably, the short cyclic peptides derived from the C-terminal sequence of Alpha1-Antitrypsin will be selected from the non-limiting group comprising Cyclo- (CPFVFLM)-SH, Cyclo-(CPFVFLE)-SH, Cyclo-(CPFVFLR)-SH, and Cyclo-(CPEVFLM)- SH, or any combination thereof. 48 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] As used herein, an "isoform" of an AAT protein, peptide or polypeptide of the invention refers to a splice variant resulting from alternative splicing of the AAT mRNA.
In some aspects, the amino acid sequence of AAT, the variant, isoform or fragment thereof, as described herein, is at least 80% identical to the corresponding amino acid sequence in SEQ ID NO: 1. In some aspects, the amino acid sequence of AAT, the variant, isoform or fragment thereof is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a corresponding amino acid sequence in SEQ ID NO: 1.
The peptide, isoform, fragment or variant thereof of the invention may preferably be conjugated to an agent that increases the accumulation of the peptide, isoform, fragment or variant thereof in the target cell, preferably a cell of the respiratory tract. Such an agent can be a compound which induces receptor mediated endocytosis such as for example the membrane transferrin receptor mediated endocytosis of transferrin conjugated to therapeutic drugs (Qian Z. M. et al., "Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway" Pharmacological Reviews, 54, 561, 2002) or a cell membrane permeable carrier which can, be selected e. g. among the group of fatty acids such as decanoic acid, myristic acid and stearic acid, which have already been used for intracellular delivery of peptide inhibitors of protein kinase C (Ioannides C.G. et al., "Inhibition of IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat by a novel peptide inhibitor of protein kinase C" Cell Immunol., 131, 242, 1990) and protein-tyrosine phosphatase (Kole H.K. et al., "A peptide- based protein-tyrosine phosphatase inhibitor specifically enhances insulin receptor function in intact cells" J. Biol. Chem. 271, 14302, 1996) or among peptides. Preferably, cell membrane permeable carriers are used. More preferably a cell membrane permeable carrier peptide is used.
In case the cell membrane permeable carrier is a peptide then it will preferably be a positively charged amino acid rich peptide.
Preferably such positively charged amino acid rich peptide is an arginine rich peptide. It has been shown in Futaki et al. (Futaki S. et al., "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery" J.
Biol. Chem., 276, 5836, 2001), that the number of arginine residues in a cell membrane 49 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] permeable carrier peptide has a significant influence on the method of internalization and that there seems to be an optimal number of arginine residues for the internalization, preferably they contain more than 6 arginines, more preferably they contain 9 arginines. An arginine rich peptide comprises preferably at least 6 arginines, more preferably at least 9 arginines.
The peptide, isoform, fragment or variant thereof may be conjugated to the cell membrane permeable carrier by a spacer (e.g. two glycine residues). In this case, the cell membrane permeable carrier is preferably a peptide.
Usually arginine rich peptides are selected from the non-limiting group comprising the HIV- TAT 48-57 peptide (GRKKRRQRRR; SEQ ID NO. 7), the FHV-coat 35-49 peptide (RRRRNRTRRNRRRVR; SEQ ID NO. 8), the HTLV-II Rex 4-16 peptide (TRRQRTRRARRNR; SEQ ID NO. 9) and the BMV gag 7-25 peptide (SEQ ID NO. 10).
Any cell membrane permeable carrier can be used as determined by the skilled artisan.
Since an inherent problem with native peptides (in L-form) is degradation by natural proteases, the peptide, isoform, fragment or variant thereof as well as the cell membrane permeable peptide, of the invention may be prepared to include D-forms and/or "retro-inverso isomers" of the peptide. In this case, retro-inverso isomers of fragments and variants of the peptide, as well as of the cell membrane permeable peptide, of the invention are prepared.
The peptide, isoform, fragment or variant thereof of the invention, optionally conjugated to an agent which increases the accumulation of the peptide in a cell can be prepared by a variety of methods and techniques known in the art such as for example chemical synthesis or recombinant techniques as described in Maniatis et al. 1982, Molecular Cloning, A laboratory Manual, Cold Spring Harbor Laboratory.
The peptide, isoform, fragment or variant thereof of the invention, optionally conjugated to an agent which increases the accumulation of the peptide in a cell as described herein are preferably produced, recombinantly, in a cell expression system. A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of E. coli, Pseudomonas, Bacillus, Streptomyces, fungi such as yeasts, and animal cells, such as CHO, YB/20, NSO, SP2/0, Rl. 1, B-W and L-M cells, African Green Monkey kidney cells (e. g., COS 1, COS 7, 50 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] BSCl, BSC40, and BMTlO), insect cells (e. g., Sf9), and human cells and plant cells in tissue culture.
By "therapeutically effective dose or amount" of an Alpha1-Antitrypsin protein, a variant, an isoform and/or a fragment thereof of the invention is intended an amount that when administered brings about a positive therapeutic or prophylactic response with respect to treatment of a subject for a disease or syndrome related to a coronavirus infection.
The term "coronavirus infection" can refer to an infection caused by a coronavirus selected from group comprising MERS-CoV, SARS-CoV and SARS-CoV-2 as well as any variant thereof. In some aspects, the SARS-CoV-2 variant described herein is a SARS-CoV-2 variant selected from the group of Lineage B.1.1.207, Lineage B.1.1.7, Cluster 5, 501.V2 variant, Lineage P.1, Lineage B.1.429 / CAL.20C, Lineage B.1.427, Lineage B.1.526, Lineage B.1.525, Lineage B.1.1.317, Lineage B.1.1.318, Lineage B.1.351, Lineage B.1.617 and Lineage P.3. In some aspects, the SARS-CoV-2 variant described herein is a SARS-CoV-2 variant described by a Nextstrain clade selected from the group 19A, 20A, 20C, 20G, 20H, 20B, 20D, 20F, 20I, and 20E. In some aspects, the SARS-CoV-2 virus described herein is a SARS-CoV-2 variant comprising at least one mutation selected from the group of D614G, E484K, N501Y, S477G/N, P681H, E484Q, L452R and P614R. In some aspects, the SARS-CoV-2 variant described herein is a SARS-CoV-2 variant derived from the variants described herein. In some aspects, the SARS-CoV-2 virus described herein is a SARS-CoV-2 variant having an at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% sequence identity to the viral genome sequence of at last one SARS- CoV-2 variant described herein.
The coronavirus infection can cause a respiratory tract infection resulting in a disease or syndrome that is a respiratory syndrome. The respiratory syndrome can be a severe acute respiratory syndrome (SARS). In some aspects, the SARS-CoV-2 infection is at least one of the three clinical courses of infections can be distinguished: (1) mild illness with upper respiratory tract manifestations, (2) non-life-threatening pneumonia and, (3) severe condition with pneumonia, acute respiratory distress syndrome (ARDS), severe systemic inflammation, organ failures, cardiovascular complications.
The composition for use of the invention may further comprise one or more pharmaceutically acceptable diluent or carrier. 51 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] "Pharmaceutically acceptable diluent or carrier" means a carrier or diluent that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes carriers or diluents that are acceptable for human pharmaceutical use.
Such pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
Pharmaceutically acceptable diluent or carrier include starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.
The pharmaceutical compositions may further contain one or more pharmaceutically acceptable salts such as, for example, a mineral acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulfate, etc.; and the salts of organic acids such as acetates, propionates, malonates, benzoates, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, gels or gelling materials, flavorings, colorants, microspheres, polymers, suspension agents, etc. may also be present herein. In addition, one or more other conventional pharmaceutical ingredients, such as preservatives, humectants, suspending agents, surfactants, antioxidants, anticaking agents, fillers, chelating agents, coating agents, chemical stabilizers, etc. may also be present, especially if the dosage form is a reconstitutable form. Suitable exemplary ingredients include macrocrystalline cellulose, carboxymethyf cellulose sodium, polysorbate 80, phenyletbyl alcohol, chiorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, parachlorophenol, gelatin, albumin and a combination thereof. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991) which is incorporated by reference herein.
Alternatively, the pharmaceutical compositions of the invention further comprises one or more additional therapeutic agent. Preferably, the one or more therapeutic agent comprises a therapeutically effective amount of one or more nucleoside analog, protease inhibitor, immune- suppressor (e.g. sarilumab or tocilizumab), chloroquine, hydroxychloroquine antibiotic, an 52 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] antibody directed against structural components of the virus, or fragment thereof (e.g. passive immunotherapy), interferon beta (e.g. interferon beta-1a) and/or a vaccine.
In certain other aspects, the pharmaceutical compositions of the invention and the one or more additional therapeutic agent will be administered substantially simultaneously or concurrently.
For example, a subject may be given a pharmaceutical composition for use of the invention while undergoing a course of treatment with the one or more additional therapeutic agent. In addition, it is contemplated that the subject has already or may be concurrently receiving other forms of antiviral therapy/ies.
In some aspects, the additional therapeutic agent may be useful to reduce the possible side- effect(s) associated with the administration of an antibody, or an antigen-binding fragment thereof, of the invention.
In some aspects, the additional therapeutic agent may be useful to support the effect associated with the administration of an antibody, or an antigen-binding fragment thereof, of the invention.
In some aspects, administration of the additional therapeutic and an antibody, or an antigen- binding fragment thereof, of the invention results in a synergistic effect regarding desired effect and/or side effect.
In some aspects, the additional therapeutic agent described herein is at least one agent selected from the group of nucleoside analog, protease inhibitor and immune modulators such as immune-suppressors.
In some aspcets, the additional therapeutic agent described herein is at least one agent selected from the group of nucleoside analog, protease inhibitor, immune-suppressor (e.g. sarilumab or tocilizumab), chloroquine, hydroxychloroquine antibiotic, an antibody directed against structural components of the virus, or fragment thereof (e.g. passive immunotherapy), interferon beta (e.g. interferon beta-1a) and/or a vaccine.
Non-limiting examples of a nucleoside analog comprise Ribavirin, Remdesivir, β-d-N4- hydroxycytidine, BCX4430, Gemcitabine hydrochloride, 6-Azauridine, Mizoribine, Acyclovir fleximer, and a combination of one or more thereof.
Non-limiting examples of protease inhibitor comprise HIV and/or HCV protease inhibitor. 53 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] In some aspects, the immune modulator described herein is interferon beta. In some aspects, the immune modulator described herein is interferon beta-1a. Non-limiting examples of immune-suppressor comprise interleukin inhibitors, such as for example IL-6 (e.g. sarilumab or tocilizumab), IL-1, IL-12, IL-18 and TNF-alpha inhibitors.
The additional therapeutic agents may improve or complement the therapeutic effect of compositions and methods described herein (see e.g. Figure 20, 11d).
Accordingly, the invention is at least in part based on the finding that certain combinations (such as IFN-beta-1a with AAT) improve the effect of AAT on viral entry and inflammation.
The present invention also contemplates a gene delivery vector and pharmaceutical compositions containing the same. Preferably, the gene delivery vector is in the form of a plasmid or a vector that comprises one or more nucleic acid encoding the AAT protein, a variant, an isoform and/or a fragment thereof of the invention. Examples of gene delivery vectors comprise e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes. The gene deliver is preferably performed in vitro or ex vivo.
Accordingly, the invention is at least in part based on the finding that AAT gene delivery (gene therapy) reduce the effect of inflammation (see e.g. Figure 19b).
In an aspect, said viral vector is a vector suited for ex-vivo and in-vivo gene delivery, preferably for ex vivo gene delivery. More preferably, the viral vector is selected from the group comprising an adeno-associated virus (AAV) and a lentivirus, e.g. Lentivirus of 1st, 2nd, and 3rd generation, not excluing other viral vectors such as adenoviral vector, herpes virus vectors, etc. Other means of delivery or vehicles are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided, in some aspects, one or more of the viral or plasmid vectors may be delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.
In other aspects of the invention, the pharmaceutical composition(s) of the invention is/are a sustained-release formulation, or a formulation that is administered using a sustained-release device. Such devices are well known in the art, and include, for example, transdermal patches, 54 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] and miniature implantable pumps that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with a non- sustained-release pharmaceutical composition.
The pharmaceutical compositions of the present invention may be administered to a subject by different routes including orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, intrapleurally, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intranasal intrathecal, and intraarticular or combinations thereof. For human use, the composition may be administered as a suitably acceptable formulation in accordance with normal human practice. The skilled artisan will readily determine the dosing regimen and route of administration that is most appropriate for a particular patient. The compositions of the invention may be administered by traditional syringes, needleless injection devices, "microprojectile bombardment gone guns", or other physical methods such as electroporation ("EP"), "hydrodynamic method", or ultrasound. The composition can also be administered by intravenous injection, intravenous infusion, infusion with a dosator pump, inhalation nasal-spray, eye-drops, skin-patches, slow release formulations, ex vivo gene therapy or ex vivo cell-therapy, preferably by intravenous injection.
The pharmaceutical compositions of the present invention may also be delivered to the patient, by several technologies including DNA injection of nucleic acid encoding the AAT protein, a variant, an isoform and/or a fragment thereof of the invention (also referred to as DNA vaccination) with and without in vivo electroporation, liposome mediated, nanoparticle facilitated, recombinant vectors such as recombinant lentivirus, recombinant adenovirus, and recombinant adenovirus associated virus sa described herein.
The compositions may be injected intra veniously or locally injected in the lung or respiratory tract or electroporated in the tissue of interest.
The present invention further provides methods of treatment and/or prevention of a disease or syndrome related to a coronavirus infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of i) an Alpha1-Antitrypsin protein, a variant, an isoform and/or a fragment thereof as described herein, or of ii) a pharmaceutical composition for use of the invention as described herein. 55 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Further provided are methods of modulating onset of coronavirus infection in a subject exposed or suspected of being exposed to coronavirus comprising, administering to the subject in need of such a treatment a therapeutically effective amount of i) an Alpha1-Antitrypsin protein, a variant, an isoform and/or a fragment thereof as described herein, or of ii) a pharmaceutical composition for use of the invention as described herein.
The present invention also related to a for determining the susceptibility of a subject of interest for treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection using a composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof as defined in herein, comprising the steps of: a) determining the level of at least one of the group consisting of endogenous alpha1- antitrypsin, at least one spike protein priming protease, ACE2 receptor and interferon- gamma in the subject of interest prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, b) determining the level of at least one of the group consisting of endogenous alpha1- antitrypsin, at least one spike protein priming protease, ACE2 receptor and interferon- gamma in at least one reference subject during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, wherein the reference subject is asymptomatic or has mild symptoms, c) comparing the level of interest determined in step a) to the reference level determined in step b), wherein the subject of interest is more susceptible for treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection if the subject of interest has at least one selected from the group consisting of: 1. a lower level of interest of endogenous alpha-antitrypsin (AAT) compared to the reference level of endogenous AAT, 2. a higher level of interest of at least one spike protein priming protease compared to the reference level of at least one spike protein priming protease, 3. a higher level of interest of angiotensin converting enzyme 2 (ACE2 receptor) compared to the reference level of the ACE2 receptor and 4. a higher level of interest of interferon-gamma (IFN-γ) compared to the reference level of IFN-γ. 56 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] All definitions and combinations provided herein apply to this aspect, if applicable and unless indicated otherwise.
The present invention further relates to a method for determining the therapeutically effective amount of alpha1-antitrypsin (AAT) for an effective treatment and/or prevention of a disease or syndrome related to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection using the composition for use of the present invention comprising the steps of: a) determining the level of endogenous alpha1-antitrypsin in a subject of interest prior to a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV- 2 infection or during a virus infection, preferably a coronavirus infection, more preferably a SARS-CoV-2 infection, b) determining the amount of AAT in the composition, which is required to achieve a level of AAT in the subject of at least 10 µM, preferably at least 20 µM, more preferably at least 50 µM, even more preferably at least 100 µM, and most preferably at least 200 µM.
All definitions and combinations provided herein apply to this aspect, if applicable and unless indicated otherwise.
In some aspects, the invention relates to the method according to the invention wherein the virus is a coronavirus. In some aspects, the invention relates to the method according to the invention, wherein the virus is a SARS-CoV-2. In some aspects, the invention relates to the method according to the invention, wherein the disease or syndrome is a respiratory syndrome or a severe acute respiratory syndrome. In some aspects, the invention relates to the method according to the invention, wherein the disease or syndrome is an inflammatory disease or syndrome of the nervous system. In some aspects, the invention relates to the method according to the invention, wherein the inflammatory disease or syndrome of the nervous system is a disease or syndrome selected from the group of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease.
All definitions and combinations provided herein apply to these aspects, if applicable and unless indicated otherwise.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that 57 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] the invention includes all such variations and modifications without departing from the spirit or essential characteristics thereof. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features. The present disclosure is therefore to be considered as in all aspects illustrated and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein. Various references are cited throughout this Specification, each of which is incorporated herein by reference in its entirety. The foregoing description will be more fully understood with reference to the following Examples.
FIGURE LEGENDS Figure 1: Schematic illustration of the SARS-CoV-2 infection cycle and AAT’s role in blocking viral-entry into the host’s cell.
Figure 2(a): Endogenous mRNA levels of Cathepsin L, Furin, ACE2 and TMPRSS2 in A549 and HeLa cells, show that neither HeLa cells, nor A549 cells express relevant amounts of ACE2 mRNA nor TMPRSS2. Both cell lines express Furin and Cathepsin L (a priming protease of spike protein from SARS-CoV-1 and SARS-CoV-2).
Figure 2(b): SARS-CoV-2 Spike D614G pseudoviral variant shows increased infectivity.
Lentiviruses expressing Luciferase and pseudotyped with SARS-CoV-2- Spike wild type (D614) or D614G mutant (G614) were used to transduce HeLa cells overexpressing or not either ACE2 and/or TMPRSS2. Results show no inhibitory effect by plasma derived AAT at micromolar (10µM) concentrations on the SARS-CoV-2 pseudoviral cell-entry in HeLa cells overexpressing TMPRSS2 and up to 25% in HeLa cells expressing ACE2 only.
Figure 3: a) ACE2 gene expression in different cell lines. b) TMPRSS2 gene expression in different cell lines (tissues).
Figure 4: ACE2 expression in A549 in response to treatment with IFN-γ.
Figure 5: ACE2 expression in HeLa in response to treatment with IFN-γ.
Figure 6: SARS-CoV-2 pseudoviral entry assay. a) to b) A549 cells - WT pseudovirus. a) A549-ACE2 cells with WT D614 pseudovirus. b) A549 – ACE2 – TMPRSS2 cells with WT D614 pseudovirus. c to d) A549 cells – spike G416 mutated pseudovirus. c) A549 ACE2 cells with mutant G416 pseudovirus. d) A549 – ACE2 – TMPRSS2 cells with mutant G614 pseudovirus. 58 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Respikam = Glassia, FDA approved plasma derived AAT (clinical grade), Sigma = plasma derived AAT bought from Sigma (non-GMP grade).
Figure 7: SARS-CoV-2 pseudoviral entry is blocked by 50-75% in ACE2 enhanced A549 cells at both 100 and 200 micromola concentrations of AAT. (Respikam 100uM in PBS 5x, Sigma 100uM in PBS 5x, Sigma 200uM in PBS 2.5x, Portland 100uM in PBS 5x, Genfaxon in PBS 5x, Camostat 10uM and 100uM in DMSO 0.2%, Bromhexine 10uM and 100uM in DMSO 0.2%, Benzenesulfonyl 10uM and 100uM in DMSO 0.2%).
Figure 8: SARS-CoV-2 pseudoviral entry is blocked by up to 45% in ACE2+TMPRSS2 enhanced A549 cells at both 100 and 200 micromolar concentrations of AAT. (Respikam 100uM in PBS 5x, Sigma 100uM in PBS 5x, Sigma 200uM in PBS 2.5x, Portland 100uM in PBS 5x, Genfaxon in PBS 5x, Camostat 10uM and 100uM in DMSO 0.2%, Bromhexine 10uM and 100uM in DMSO 0.2%, Benzenesulfonyl 10uM and 100uM in DMSO 0.2%).
Figure 9 ACE-2 is the host cell receptor responsible for mediating infection by SARS-CoV-2, the novel coronavirus responsible for coronavirus disease 2019 (COVID-19). Treatment with a drug compound (AAT) disrupts the interaction between virus and receptor. (Adapted from https://www.rndsystems.com/resources/articles/ace-2-sars-receptor-identified).
Figure 10: SARS-CoV-2 pseudoviral entry assay protocol.
Figure 11 a) b) Effect of plasma derived and recombinant AAT on SARS-CoV-2 pseudovirus entry in ACE2 overexpressing A549 human lung alveolar basal epithelium cells. Most pronounced inhibitory effect (93.4%) is observed at 200uM for Recombinant AAT 1 produced in CHO cells using vector pXC17.4 (Lonza Biologics Plc) c) Effect of other serine protease inhibitors on SARS-CoV-2 pseudovirus entry in ACE2 overexpressing A549 human lung alveolar basal epithelium cells d) IFN-beta-1a at 10ng/mL in combination with 25uM plasma- derived AAT and recombinant AAT produced in CHO cells (Recombinant AAT 1, Recombinant AAT 2) show an additive inhibitory effect in a SARS-CoV-2 pseudoviral entry assay.
Figure 12 a) b) Effect of plasma derived and recombinant AAT on SARS-CoV-2 pseudovirus entry in ACE2 overexpressing HeLa human cervical cancer cells c) Effect of other serine protease inhibitors on SARS-CoV-2 pseudovirus entry in ACE2 overexpressing HeLa human cervical cancer cells.
Figure 13 Schematic illustration of the SARS-CoV-2 spike fusion assay.
Figure 14 SARS-CoV-2 spike fusion assay in HeLa human cervical cancer cells overexpressing either ACE2 and small bit luciferase or SARS-CoV-2 spike and large bit luciferase. Recombinant AAT (rhAAT) produced in CHO cells (Recombinant AAT 1 and 59 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Recombinant AAT 2) shows a better inhibitory effect on SARS-CoV-2 spike mediated cell fusion compared to plasma derived AAT.
Figure 15 a) qPCR analysis of spike protein priming protease gene expression in human lung cell line b) qPCR analysis of ACE2 gene expression in human lung cell line (Calu 3 and A549), shows no endogenous expression of ACE2 in the A549 cell line c) qPCR analysis of TMPRSS2 gene expression in human lung cell line (A549) versus a coloreactal cell line (Caco2), shows no endogenous expression of TMPRSS2 in the A549 cell line d) e) Relative quantative qPCR analysis of spike protein priming protease gene expression in various human cell lines (tissues).
Evidently, cells originating from the lungs display the highest copy number for Trypsin and Cathepsin B, in Calu3 and A549 cells, respectively. Notably, cells derived from neural tissue (SH-SY5Y) also display a realtively high copy number for both Trypsin and Cathepsin B.
Figure 16 a) AAT and rhAAT inhibits cathepsin B protease activity b) AAT and rhAAT inhibits cathepsin L protease activity, with the most pronounced inhibitory effect observed for recombinant AAT produced in HEK293 cells with vector pcDNA3.1(+) (Recombinant AAT 4) c) AAT and rhAAT inhibits trypsin protease activity, with the most pronounced inhibitory effect observed for recombinant AAT produced in HEK293 cells with vector pcDNA3.1(+) (Recombinant AAT 4) d) AAT and rhAAT inhibits furin protease activity, with the most pronounced inhibitory effect observed for recombinant AAT produced in HEK293 cells with vector pcDNA3.1(+) (Recombinant AAT 4) e) AAT and rhAAT inhibits PC1 protease activity f) AAT and rhAAT inhibits matriptase protease activity g) AAT and rhAAT inhibits TMPRSS2 protease activity h) AAT and rhAAT inhibits elastase protease activity, with the most pronounced inhibitory effect observed for recombinant AAT produced in CHO cells with vector pXC17.4 (Recombinant AAT 1) i) AAT and rhAAT inhibits neutrophil elastase protease activity, with the most pronounced inhibitory effect observed for recombinant AAT produced in HEK293 cells with vector pcDNA3.1(+) (Recombinant AAT 4).
Figure 17 Standard curve for binding of a) plasma derived AAT and b) recombinant AAT measured using Octet method. Different binding affinity is observed between the plasma derived AAT and the recombinant AAT produced in CHO cells with vectors PL136 and 137.
Figure 18 a) Schematic illustration of the experimental timeline b) IFNγ-mediated microglial activation (inflammation).
Figure 19 a) Schematic illustration of the experimental timeline b) AAT decreases IFNγ- mediated microglial activation (inflammation). Effect is observed for plasma derived AAT, recombinant AAT (rhAA) and for cells transduced with a gene expressing AAT (gene therapy). 60 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Figure 20 a) Schematic illustration of the experimental timeline b) IFNβ improves the anti- inflammatory effect obtained with AAT.
Figure 21 a) b) Effect of plasma derived and recombinant AAT on MERS-CoV pseudovirus entry in Caco2 human colorectal adenocarcinoma cells c) Effect of other serine protease inhibitors on MERS-CoV pseudovirus entry in Caco2 human colorectal adenocarcinoma cells.
Figure 22 a) b) Effect of plasma derived and recombinant AAT on SARS-CoV pseudovirus entry in ACE2 overexpressing A549 human lung alveolar basal epithelium cells c) Effect of other protease inhibitors on SARS-CoV pseudovirus entry in ACE2 overexpressing A549 human lung alveolar basal epithelium cells.
Figure 23 a) impact of AAT on ADAM17 activation and protein shedding b) impact of AAT on activation of monocyte/macrophages by spike protein/IgG immune complexes.
Figure 24 Differences in molecular weight of AAT from different sources.
Figure 25 a) Vector map for pXC-17.4 (Lonza Biologics) b) Vector map for pJ201_AAT_native_SP (Merck) c) Vector map for pJ201_AAT_SP5 (Merck) d) Vector map for PL136 (Merck) e) Vector map for PL137 (Merck) f) Vector map for empty pCGS3 vector g) Vector map for pcDNA3.1(+) (GenScript).
Figure 26 Octet method developed for the detection of AAT affinity.
All Figures: "Respikam" refers to Plasma derived AAT (clinical-grade); "Sigma" refers to Plasma derived AAT; "Recombinant AAT 1" refers to AAT produced in CHO by pXC-17.4 (GS System, Lonza), "Recombinant AAT 2" refers to AAT produced in CHO by PL136/PL137 (Merck), "Recombinant AAT 3" refers to AAT produced in HEK293T; "Recombinant AAT 4" refers to AAT produced in HEK293 by pcDNA3.1(+) (GenScript). 61 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] EXAMPLES Materials & Methods Treatment of SARS-CoV-2 infection by Alpha1-Antitrypsin (AAT) The impact of AAT on SARS-CoV-2 infection is shown on two levels: 1. First, the protease-dependent entry of SARS-CoV-2 into cells 2. Second the overshooting inflammation in severe SARS-CoV-2 disease Importantly, this represents three stages of the COVID-19 (i.e. the disease caused by SARS- CoV-2): 1. First stage COVID-19 (disease caused by SARS-CoV-2, flue-like symptoms, usually disappearing within one week) does not require treatment. 2. Second stage disease, typically characterized by viral pneumonia, requires hospital and an antiviral treatment (i.e. inhibition of SARS-CoV-2 entry into cells) is of major interest at this stage to prevent further progression. 3. Third stage COVID disease is characterized by acute respiratory distress syndrome (ARDS) and severe systemic inflammation; this stage requires an anti-inflammatory and antiviral treatment.
According to our analysis, AAT is useful for the treatment of stage II and stage III COVID-19 whereas prophylactic administration of AAT is envisaged in order to prevent the development of stage I into stage II and III.
Example 1 - Entry of SARS-CoV-2 into cells The entry of SARS-CoV-2 is mediated by the binding of the viral spike protein with the host cell Angiotensin converting enzyme 2 (ACE2) receptor. To recapitulate in-vitro this biological event, lentivectors coding for a reporter (GFP or luciferase) and expressing the spike protein on its surface are generated. The cellular entry of the lentivector is mediated by the SARS-CoV-2 mechanism, the efficiency of which is measured by the expression of the reporter (GFP or luciferase) in the target cells (Ou, X., Liu, Y., Lei, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS- 62 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] CoV. Nat Commun 11, 1620, 2020). AAT is added to quantify inhibition on viral entry by reading out the GFP and/or luciferase signals.
The transmembrane Serine Protease TMPRSS2 is crucial for SARS-CoV-2 infection (Toshio Hirano, Masaaki Murakami COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome Immunity, 22 April 2020) and for Hepatitis C infection (Esumi M, Ishibashi M, Yamaguchi H, Nakajima S, Tai Y, Kikuta S, Sugitani M, Takayama T, Tahara M, Takeda M, WakitaT- Trans-membrane serine protease TMPRSS2 activates hepatitis C virus infection.
Hepatology. 2015 Feb; 61(2):437-46). The hepatitis C infection can be blocked by AAT (presumably through TMPRSS2 inhibition – Esumi et al., 2020), SARS-CoV-2 (as well as some highly pathogenic forms of influenza virus) has a sequence that allows cleavage by the protease furin. This cleavage site is not present in the SARS and the MERS coronaviruses, suggesting that it is important for pathogenicity of SARS-CoV-2 (B. Coutard, C. Valle, X. de Lamballerie, B. Canard, N.G. Seidah, E. Decroly, The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antiviral Research,Volume 176, 2020). Alpha1-antitrypsin Portland has a strong and selective activity on furin (Jean F, Stella K, Thomas L, et al. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci U S A. 1998;95(13):7293– 7298. doi:10.1073/pnas.95.13.7293). It is, therefore, envisaged that wild type AAT (plasma derived) as well as recombinant (produced in mammalian cells, e.g. CHO and/or HEK cells) would display furin activity.
Experiments 1.1. Impact of AAT on cellular cleavage of recombinant spike protein Recombinant spike protein is added to relevant cell types (any ACE2 expressing cells and known in the art) and proteolytic cleavage is assessed by Western blotting. Any ACE2 expressing cell-lines can be used. Multiple target cell lines express various amount of the ACE2 receptor, include but are not limited to; Calu-3, SH-SY5Y, HEK, HT1080, A549, MRC 5, Huh7, Vero81, VeroE6, Hela, RS and LLCMK2. 1.2. Impact of AAT on entry of pseudoviruses Pseudoviruses (i.e. pseudotyped viral vectors) that use the SARS-CoV-2 spike protein as viral attachment/fusion protein correctly depict the mechanisms of SARS-CoV-2 into cells. This entry is dependent on two proteolytic steps which are inhibited by the protease inhibitor AAT. 63 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Therefore, the entry of pseudo-viruses in a variety of different cell lines, preferably ACE2 expressing cell-lines are investigated. 1.3. Impact of AAT on cellular infection by active SARS-CoV-2 (live virus tests): AAT is tested on live SARS-CoV-2 virus manipulated under biosecurity level 3 in accordance with OFSP recommendations. The virus is inoculated in-vitro on cells treated with AAT, or any fragment, variant and isoform thereof as multiple parameters are measured to assess efficiency including reduced cytotoxicity and viral titer. More specifically, cellular infection with SARS- CoV-2 is assessed by immunofluorescence with viral proteins as well as quantification of cell death. Since SARS-CoV-2 infect neural tissue (Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection [published online ahead of print, 2020 Apr 15]. N Engl J Med. 2020; Pleasure SJ, Green AJ, Josephson SA. The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection: Neurologists Move to the Frontlines. JAMA Neurol. Published online April 10, 2020), infection of neural tissue (e.g. Minibrain™) as well as neuroblastoma cells (SH-SY5Y) will be performed as co- treatment with AAT and is expected to modify viral cytotoxicity or tropism.
Example 2 - Overshooting inflammation in severe SARS-CoV-2 disease also known as "Cytokine Storm"¸ Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools [published online ahead of print, 2020 Mar 3]. Virol Sin. 2020;1–6. doi:10.1007/s12250-020-00207-4): 9 Mechanism of SARS-CoV-2 induced inflammation Activity of AAT Inflammation Caused by Rapid Viral inhibition of viral entry Replication and Cellular Damage Inflammation Caused by Virus-Induced ACE2 inhibition of ADAM17 Downregulation and Shedding Inflammatory Responses Induced by Anti- 64 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Spike IgG (Anti-S-IgG) Proteolysis was shown to enhance also monocyte FcyRJI-mediated functions, such as antibody-dependent cellular cytotoxicity and induction of TNF-cu release.
Experiments 2.1. SARS-CoV-2 activation of ADAM17 (TACE): ADAM17 activation part of SARS-CoV-2 pathology (see, e.g. Vanesa Palau, Marta Riera, María José Soler, ADAM17 inhibition may exert a protective effect on COVID-19, Nephrology Dialysis Transplantation, , gfaa093, https://doi.org/10.1093/ndt/gfaa093; https://clinicalaffairs.umn.edu/umn- research/regulation-sars-cov-2-receptor-ace2-adam17; Haga S, Yamamoto N, Nakai- Murakami C, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS- CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U S A. 2008;105(22):7809–7814. doi:10.1073/pnas.0711241105). AAT inhibits ADAM17 (see, e.g. Bergin DA, Reeves EP, Meleady P, et al. α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010;120(12):4236–4250. doi:10.1172/JCI41196; Serban KA, Petrusca DN, Mikosz A, et al.
Alpha-1 antitrypsin supplementation improves alveolar macrophages efferocytosis and phagocytosis following cigarette smoke exposure. PLoS One. 2017;12(4):e0176073. Published 2017 Apr 27. doi:10.1371/journal.pone.0176073).
Investigate the impact of AAT on ADAM17 activation and protein shedding (in particular ACE2) after exposure of cells to (Figure 23a): i) spike protein ii) pseudovirus iii) SARS-CoV-2 (live virus).
Most relevant cells to be used are any ACE2 expressing cells (as listed above). 2.2. Activation of Fc receptors by SARS-CoV-2/IgG immune complexes (antibody-dependent enhancement see e.g. F. Negro, Swiss Med Wkly. 2020;150:w20249 "Is antibody-dependent 65 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] enhancement playing a role in COVID-19 pathogenesis?"). Proteolysis through trypsin-like proteases enhances monocyte FcyRJI-mediated functions, such induction of TNF release (J M Debets, J G Van de Winkel, J L Ceuppens, I E Dieteren, W A Buurman in The Journal of Immunology February 15, 1990, 144 (4) 1304-1310).
Investigate impact of AAT on activation of monocyte/macrophages by spike protein/IgG immune complexes (Figure 23b).
Example 3 - Additional experiments in support of AAT efficacy in decreasing viral proliferation 3. Viral polymerase assay The SARS-CoV-2 viral polymerase is a key element in the replication of the viral genetic material. A cell-line cell line expressing the multi-subunit viral polymerase (constituted of at least the 3 core subunits NSP7, NSP8 and NSP12) is transfected to also overexpress a luciferase reporter which can only be activated by the viral polymerase activity.
The luciferase reporter signal is proportional to the viral polymerase activity. AAT is tested to assess viral polymerase inhibition activity.
Upon entry in the host cell, SARS-CoV-2 will use the host cell machinery to enhance its own replication. This will induce a toxic response on the host cell, essentially mediated by the NSP1 viral protein.
To mimic this biological event a cell-line expressing the viral NSP1 protein controlled by a tetracycline-inducible promoter is generated. Following the cells’ treatment with tetracycline the toxic NSP1 protein will be expressed. Addition of AAT is presumed to inhibit this toxic effect mediated by the viral protein.
Experiment 4 Introduction The recent pandemic caused by the newly emerged SARS-CoV-2 Coronavirus took the world by surprise. As opposed to previous Coronavirus outbreaks such as SARS and MERS, the new virus is not characterized by a particularly high case-fatality rate, but rather by an unprecedented epidemiological success. And indeed, the virus has so far largely resisted to all attempts of eradication, despite stringent measures taken in many countries around the globe. 66 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] SARS-CoV-2 is an RNA virus, but Coronaviruses differ from other RNA viruses in several respects. They have a large genome and a sophisticated life cycle which is still poorly understood. Also, coronaviruses have a proof-reading machinery, which confers a relatively stable genome, as compared to other types of RNA viruses. And indeed, given the size of the pandemic, so far relatively few mutations leading to amino acid changes have been reported.
The coronavirus S protein, also known as spike, is the dominant protein of the viral envelop. It mediates the attachment of the virus to the host cell surface receptors and subsequent fusion between the viral and host cell membranes to facilitate viral entry into the host cell. It is a trimeric class I fusion protein which exists in a metastable pre-fusion conformation divided in two main subunits, namely S1 and S2. In order to attach to the host cell surface receptors, the receptor binding domain (RBD) contained within the S1 domain undertakes a hinge-like conformational change, defining two different states [1]. This conformational change is required for proteolytic processing and/or fusion of the S2 domain with the host cell membrane.
It is now thought that a variety of proteases including PC family of proteases, trypsin-like proteases, and cathepsins are able to cleave the spike protein [2].
The spike protein D614G mutation has received attention as it could potentially alter viral attachment, fusogenicity, and/or immunogenicity. The D614G mutation has been suggested to increase infectivity (ref), transmissibility [3] and/or case fatality rate [4]. More recent studies directly demonstrate that the G614 variant indeed enhances viral entry into cells [5, 6].
SARS-CoV-2 employs a multi-subunit replication/transcription machinery [7]. A set of non- structural proteins (nsp) produced as cleavage products of the ORF1a and ORF1b viral polyproteins assemble to facilitate viral replication and transcription, making this machinery a potential target for therapeutic intervention against COVID-19 viral infections [8]. RNA- dependent RNA polymerase (RdRp, also known as nsp12) is a key player in the synthesis of viral RNA. Recently resolved crystal structure of SARS-CoV-2 nsp12 in complex with its nsp7 and nsp8 co-factors underlines the central role these non-structural proteins have in the replication and transcription cycle of the COVID-19 virus [8, 9]. The P314L mutation of the RdRp has received less attention, however it has been suggested that this mutation might alter viral proof reading and thereby lead to an increased down-stream mutation rate [10].
In this study, we investigate the emergence of a SARS-CoV-2 variant with concomitant mutations in the S protein and the RdR-polymerase. Both mutations are in strategically relevant sites of the respective proteins and hence candidates to alter the biology of the virus. The 67 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] G624/L323 variant, but not the individual G624 or L323 mutants, is epidemiologically highly successful and over the last months has largely replaced the original D624/P323 variant.
Methods: Cell lines and culture Human cell lines used in the study were HEK 293T/17 (human kidney, ATC C#CRL-11268), Luc Luc A549, HeLa and HMC3-MHCII cells. HMC3-MHCII cell line coding for luciferase reporter under major histocompatibility complex II promoter (MHCII) has been described as a valuable tool to study human microglial activation by and was obtained from Prof. Karl-Heinz Luc Krause at the University of Geneva. HMC3-MHCII cells were transduced with a lentiviral Luc AAT vector to obtain an AAT-producing HMC3-MHCII ;Ubi cell line (See Lentivirus production). Cells were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 μg/ml of penicillin and streptomycin, 2 mM l-glutamine, 1 mM sodium pyruvate and 1% non-essential amino acids.
HMC3 cell lines were not added non-essential amino acids. Cultureds were maintained at 37˚C in a 5% CO2 atmosphere.
Spike fusion assay.
Suited concentration of treatments was pre-diluted in culture media. On the top of this mix was added the HeLa cell line stably overexpressing the human ACE2 receptor and the Smallbit split- luciferase fragment together with the HeLa cell line stably overexpressing the SARS-CoV-2 spike protein and the Largebit split-luciferase fragment, and incubated at 27°C for 24h.
Interaction between ACE2 and SARS-CoV-2 spike mediates the fusion of both cell line, thus interactions between the largebit and smallbit split luciferase fragments which leads to a functional luciferase. Light emission was measured with the Nanoglo kit (Promega) according to manufacturer instructions.
Generation of cell lines expressing ACE2 and TMPRSS2.
Hela and A549 cells were plated at a density of 2E05 cells per well in a 12 well plate. The day after cells were co-transduced either with ACE2/puromycin and/or TMPRSS2/blasticidin lentiviruses. Four day after transduction, cells were selected with blasticidin amd puromycin at 5 μg/ml. Cells were maintained as polyclonal population.
Plasmids ACE2 and TMPRSS2 cDNA ORFs were purchased from GenSript and were cloned into pCDH- CMV-MCS-EF1α-Puro (SEQ ID NO: 13) and pCDH-CMV-MCS-EF1α-Blast (SEQ ID NO: 14) lentivectors respectively using standard cloning methods. pCG1_SCoV2-S plasmid (SEQ 68 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] ID NO: 15) encoding SARS-CoV-2-Spike protein was provided by Prof. Dr. Stefan Pöhlmann (University Göttingen, Göttingen, Germany). G614 Spike was cloned using site-directed mutagenesis with the following primers: 5’-GCGTGAACTGTACCGAAGTG-3’ (SEQ ID NO: 16) and 5’-CCTGGTACAGCACTGCC-3’ (SEQ ID NO: 17). C-terminal 19 amino acids truncated version of the SARS-CoV-2-Spike was generated by PCR amplification using primers 5’-AGCGAATTCGGATCCGCC-3’ (SEQ ID NO: 18) and 5’- ACAGTCGACTCTAGATTAGCAGCAGCTGCCACAG-3’ (SEQ ID NO: 19) followed by cloning into pCG1 plasmid.
AAT purification produced in HEK293T cells Supernatant from HEK293T cells overexpressing human AAT-His tagged was sampled and incubated overnight at 4°C under shaking with Ni Sepharose excel histidine-tagged protein purification resin (Cytiva). Volume ratio supernatant:resine is 200:1. Then supernatant was discarded, and beads were washed once with phosphate-buffered saline (PBS). Beads were washed once times with PBS supplemented by 10% (v/v) elution buffer (PBS supplemented with 500 mM imidazole, pH 7.5), and once with PBS supplemented with 20% elution buffer.
Finally purified AAT-His-tagged was eluted in 100% elution buffer. Imidazole was removed by dialysis to obtain AAT-His in PBS buffer.
Lentivirus production For recombinant-lentivirus production, plasmids were transfected in HEK293T cells using the 6 calcium phosphate method. Briefly, 4.5x10 cells were plated in a 10-cm dish and transfected 16h later with 15 μg of either ACE2, TMPRSS2, AAT or empty-expressing lentiviral vectors, μg of packaging plasmid (psPAX2, gift from Didier Trono [Addgene plasmid 12260]) and μg of envelope (pMD2G, gift from Didier Trono [Addgene plasmid 12259]). The medium was changed 8h post-transfection. After 48h, the viral supernatants were collected and filtered using 45 µm PVDF filters and stored at -80°C.
Coronavirus spike pseudotyped Lentiviral production Spike-pseudotyped lentivirus were produced by co-transfection 293T cells with psPAX2, pCDH-CMV-Gluc-EF1α- GFP, and plasmids encoding either SARS-CoV-2 Spike D614 Full length (FL) (SEQ ID NO: 15), Spike G614 Full length (FL) (SEQ ID NO: 20), Spike D614 DeltaCter (SEQ ID NO: 21), Spike G614 DeltaCter (SEQ ID NO: 22), SARS-CoV spike (Sino Biological Europe GmbH, Catalog Number: VG40150-G-N), MERS-CoV spike (Sino Biological Europe GmbH, Catalog Number: VG40069-G-N) or empty vector (SEQ ID NO: 23) by using the calcium phosphate method as described above. 69 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Coronavirus spike pseudotyped Lentiviral Infectivity Assays HeLa stably overexpressing the human ACE2 receptor, A549 cells stably overexpressing the human ACE2 receptor or Caco2 cells were seeded into 96-well plates. 3 hours after plating, compound treatment was performed, or omitted depending on the experimental setup. 24h later cells were transduced with coronavirus pseudovirus for 6h. Then culture media was changed and cells were kept at 37°C. After three-day incubation, Gaussia luciferase activity was measured by the addition of 10uL cell supernatant to 50uL of phosphate-buffered saline [PBS] supplemented with 4 μM coelenterazine and immediately measuring luminescence in a luminometer (Glomax; Promega). In parallel the cells were trypsinized and resuspended in PBS supplemented with 10% FBS and were analysed by flow cytometry using Attune NxT Flow Cytometer(thermofisher Scientific). Data was analysed using FlowJo 11 (FlowJo, LLC, Ashland, OR).
Cell free assay (spike protein priming protease inhibition) The reaction was performed in 100 ul for trypsin (Sigma-Aldrich), 75 ul for cathepsin B (R&D Systems) and 50 ul for PC1 (R&D Systems), matriptase (R&D Systems), furin (NEB), cathepsin L (R&D Systems) and TMPRSS2 (creative biomart). Buffer is composed of PBS pH 7.4 for trypsin (diluted to 6.4nM) ; 25 mM MES, pH 5 for cathepsin B (diluted to 1.76ng/ul) ; mM MES, 5 mM CaCl2, 1% Brij-35, pH 6 for PC1 (diluted to 1.76ng/ul); 50 mM Tris, 50 mM NaCl, 0.01% Tween 20, pH 9 for matriptase (diluted to 1.76 ng/ul); 100 mM HEPES, 1 mM CaCl2, 0.5% Triton X100, 1 mM 2-Mercaptoethanol, pH 7.5 for furin ( diluted to 10U/ml) ; 0.005% Brij-35, 1 mM EDTA, 5 mM DTT, 50 mM MES, pH 6 for cathepsin L (diluted to 1.76ng/ul); 50 mM TrisHCl, 150 mM NaCl, 0.01% tween 20, pH 8 for TMPRSS2 (diluted to 0.5uM). Unless specified all reagents were provided by Sigma Aldrich. For trypsin, cathepsin B, PC1, matriptase, furin, cathepsin L assays, SARS-CoV-2 peptide composed of the sequence TNSPRRARSVA with modification MCA/Lys (DNP) FRET pair (Biomatik) was used. For TMPRSS2 assay, peptide composed of the sequence Boc-QAR-AMC (R&D Systems) was used.
For elastase ELA1 from pig pancreas, assay kit (E-12056) was purchased from molecular probes (Sigma-Aldrich) and for neutrophil elastase ELA2, assay kit (BML-AK497) was purchased from Enzo, tests were performed according to manufacturer instructions.
Fluorescence or absorbance was measured every minute for 45 minutes in plate reader. Vmax was determined for each condition as fluorescence unit per minute and enzymatic activity is expressed in percentage of untreated condition. 70 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Gene expression analysis Total RNA was isolated using RNeasy Micro Kit (Qiagen) according to the manufacturer’s instructions. 500ng of total RNA from each sample were reverse transcripted with Primescript kit from Takara in a total volume of 10 µl, at 37°C for 15min. The relative mRNA levels were evaluated by quantitative RT-qPCR using SYBR Green PCR kit (Applied Biosystems) by 2 delta Ct method. GAPDH was used as internal control.
Gene copy number estimation For copy number, linearization of each specific plasmid was performed using restriction enzyme digestion. The product of digestion was cleaned using PCR clean up kit (GeneJET) according to manufacturer instructions.Then optical density was measured and copy number determined. A serial dilution of 1/10 from digested plasmid was used for qPCR.
Plasmids for furin, cathepsinL, matriptase (stl4), trypsin (PRSS1), PC1 (PCSK1) were provided by GenScript and plasmid for cathepsin B was provided from Sino Biological.
Primers Gene Oligo sequence (5' to 3') GGAACATGACAGCTGCAACT Furin Forward (SEQ ID NO: 32) TCGTCACGATCTGCTTCTCA Furin Reverse (SEQ ID NO: 33) TAGAGGCACAGTGGACCAAG Cathepsin L Forward (SEQ ID NO: 34) ATGGCCATTGTGAAGCTGTG Cathepsin L Reverse (SEQ ID NO: 35) TCTCTGACCGGATCTGCATC Cathepsin B Forward (SEQ ID NO: 36) TCACAGGGAGGGATGGAGTA Cathepsin B Reverse (SEQ ID NO: 37) GCGTGCCTGAGAAGAAAGAG PC1 Forward (SEQ ID NO: 38) PC1 Reverse ATCCCGTTCTCTTTCAGCCA 71 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] (SEQ ID NO: 39) AAGTGTGAAGCCTCCTACCC Trypsin Forward (SEQ ID NO: 40) GGTGTAGACTCCAGGCTTGT Trypsin Reverse (SEQ ID NO: 41) CCCAACAACCAGCATGTGAA Matriptase Forward (SEQ ID NO: 42) ACTGGAGTCGTAGGAGAGGT Matriptase Reverse (SEQ ID NO: 43) AGAACGTCCTGCTCATCACA Matriptase Forward (SEQ ID NO: 44) TGTGCAGTCAATGTTGGGTG Matriptase Reverse (SEQ ID NO: 45) Results: Impact of the S protein D614G mutation on cell transduction with pseudotype lentivectors Our aim was to establish cell lines that consistently express the viral receptor ACE2, as well as relevant proteases able cleave the spike protein. As seen in Figure 3A and B, neither Hela cells, nor A549 cells expressed relevant amounts of ACE2 mRNA. Similarly, mRNA levels of TMPRSS2 were almost undetectable. Both cell types show a low to intermediate gene expression of furin, but relatively high level gene expression of cathepsin L (a protease able to cleave spike protein from both, SARS-CoV-1 and SARS-CoV-2). In order to establish cell lines permissive for spike protein pseudotyped lentivectors, we therefore transduced both Hela cells and A549 cells either individually, or combined with ACE2 (SEQ ID NO: 24) and TMPRSS2(SEQ ID NO: 25).
As expected, exposure of wild type (mock-transduced) Hela cells or A549 cells to the above described lentivectors did not lead to GFP or luciferase expression (Figure 3c-f). Similarly, overexpression of TMPRSS2 by itself did not lead to significant transduction rate. Using the D614 pseudotype lentivector, there was a small, yet clearly detectable transduction of the ACE2 and ACE2/TMPRSS2-expressing Hela cells, but only a very small transduction of A549 cells.
This changed markedly when the G614 pseudotype vector was used. There was a much stronger 72 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] transduction of both ACE2-expressing lines. Note however that transduction of ACE2- expressing HeLa cells was much stronger than the one of ACE2-expressing A549 cells.
Conversely, the overexpression of TMRPSS2 in addition to ACE2, lead to strong additional enhancement of transduction, which was not the case for Hela cells. Thus, most likely Hela cells already strongly express a spike cleaving protease, and the overexpression of TMRPSS2 is not required for efficient transduction. In contrast, in A549 cells, proteolytic cleavage appears to be a rate-limiting step, and overexpression of TMRPSS2 therefore enhances transduction.
Discussion (HeLa versus A549 cell-line susceptibility to viral infection) The increased susceptibility of one cell-line (HeLa, cervical, female, Afro-american origin) to SARS-CoV-2 pseudoviral infection is a particularly interesting observation versus another cell- line (A549, lungs, male, Caucasian origin) as it underlies the concept that characterization of patient populations is key to determining a therapeutic strategy tailored towards achieving maximal impact for patients either diagnosed with COVID-19 or otherwise for prophylactic purposes. Although race in itself might present a secondary role for consideration, genetic predisposition for either low endogenous AAT or higher levels of chronic inflammation (higher IFN-γ and/or cathepsin L) for instance require higher doses and/or more regular administration of the active therapeutic substance (AAT).
Experiment 4 The aim was to detect the endogenous levels of ACE2 and TMPRSS2 gene expression in different cell lines.
Method: Total RNA was extracted from Calu3, CaCo2, VeroE6, HepG2, A549, SH-SY5Y, HEK293-117T, HeLa, cell lines using RNeasy Micro Kit (Qiagen). Complementary DNA was synthesized from total RNA using PrimeScript™ RT Reagent kit (Takara). The real-time PCR measurement of cDNAs was performed using PowerUp SYBR™ Green Master Mix (Applied Biosystems) and normalized to the expression of GAPDH as control housekeeping gene. The primers are listed below: ACE2 forward: cattggagcaagtgttggatctt (SEQ ID NO: 26) ACE2 reverse: gagctaatgcatgccattctca (SEQ ID NO: 27) TMPRSS2 forward: cacggactggatttatcgacaa (SEQ ID NO: 28) 73 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] TMPRSS2 reverse: cgtcaaggacgaagaccatgt (SEQ ID NO: 29) GAPDH forward: gcacaagaggaagagagagacc (SEQ ID NO: 30) GAPDH reverse: aggggagattcagtgtggtg (SEQ ID NO: 31) The results are shown in Figure 3.
Experiment 5 The aim was to determine whether Interferon gamma treatment induces ACE2 expression in A549 cell line.
Protocol: A549 cells were seeded in 12 well plate and the addition of interferon gamma was performed 24 hours post cell splitting. The treatment lasted for 48 hours and we performed RNA extraction, reverse transcriptase reaction and qPCR as previously described (cf. method section of Experiment 4).
The results are shown in Figure 4.
Experiment 6 The aim was to determine whether interferon gamma treatment induces ACE2 expression in HeLa cells expressing the SARS-CoV-2 fusion protein.
Protocol: HeLa Spike cells were seeded in 12 well plate and the addition of interferon gamma was performed 24 hours post cell splitting. The treatment lasted for 48 hours and we performed RNA extraction, reverse transcriptase reaction and qPCR as previously described (cf. method section of Experiment 4).
The results are shown in Figure 5.
Experiment 7: SARS-CoV-2 viral entry assay The results are shown in Figure 7 and 8. Done with pseudolentivector expressing the surface protein SARS-CoV-2 spike harboring the D614G mutation, coding for a luciferase reporter (Figure 7 and 8).
The pseudolentivector is added on A549 cells overexpressing constitutively the ACE2 receptor (Figure 7) or both ACE2 and TMPRSS2 (Figure 8 ). Compound treatment is either performed 74 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 24h (panels A&B) or 1h (panels C&D) prior to addition of the pseudolentivector. Further schematic information on the pseudoviral assay protocol is provided in Figures 9 and 10.
Example 4 Viral entry inhibition test with A549 human lung alveolar basal epithelium cells overexpressing ACE2 (Figure 11 and 22) or Caco2 human colorectal adenocarcinoma (Figure 21) were treated for 24h with AAT from multiple sources (Figure 11a,11b, 21a, 21b, 22a, 22b) or with inhibitor compounds (Figure 11c, 21c, 22c). Then the lentivector coding for the luciferase reporter and expressing the SARS-CoV-2 spike protein with the D614G mutation (Figure 11), the SARS- CoV spike protein (Figure 22) or the MERS-CoV spike protein (Figure 21) was added for 6h.
Finally, the culture media was changed, and cells were incubated for 3 additional days prior to measurements. Viral entry was measured by the lentivirus-mediated luciferase signal (Figure 11, 21, 22 dark grey) and normalized with WST8-cell viability displayed as light grey. For all conditions the concentrations of DMSO / PBS have been normalized (buffer). All conditions were performed in triplicate, error bars represent standard deviation. Please refer to material and method section for technical information.
Example 5 Viral entry inhibition test with HeLa human cervical cancer cells overexpressing ACE2 were treated for 24h with AAT from multiple sources (Figure 12a, 12b) or with inhibitor compounds (Figure 12c). Then the lentivector coding for the luciferase reporter and expressing the SARS- CoV-2 spike protein with the D614G mutation was added for 6h. Finally, the culture media was changed, and cells were incubated for 3 additional days prior to measurements. Viral entry was measured by the lentivirus-mediated luciferase signal (dark grey) and normalized with WST8- cell viability displayed as light grey. For all conditions the concentrations of DMSO/PBS have been normalized (buffer). All conditions were performed in triplicate, error bars represent standard deviation. Please refer to material and method section for technical information.
Example 6 SARS-CoV-2 spike fusion assay. The principle of the test is depicted in Figure 13. HeLa human cervical cancer cells overexpressing either ACE2 and small bit luciferase or SARS-CoV-2 spike and large bit luciferase were mixed at equal number with the suited concentration of treatment. 24h later the cell fusion was measured by the amount of luciferase reporter signal. Luciferase signal are observed in function of the buffer control. Sera was diluted at final concentration of 75 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 1/16. For all conditions the concentrations of Sera / PBS have been normalized (buffer). All conditions were performed in triplicate, error bars represent standard deviation (Figure 14).
Please refer to material and method section for technical information.
Example 7 Quantitative PCR analysis was performed to determine gene copy number of proteases in A549 cell. Copy number was calculated using linear plasmid for each gene as a control (Figure 15 a).
Please refer to material and method section for technical information.
Example 8 Quantitative PCR analysis was performed to determine relative gene expression of proteases ACE2 (Figure 15 b) and TMPRSS2 (Figure 15 c) in A549 cells. Calu3 and Caco2 cell lines were used as reference for respectively ACE2 and TMPRSS2 expression. Gapdh gene was used to normalize. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 9 SARS-CoV-2 peptide 50uM, cathepsin B recombinant protein 1.76ng/ul and AAT at luM were incubated together for 45 min. Fluorescence was measured every minute in a UV spectrophotometer (excitation at 330nm and emission detection at 390nm) (Figure 16 a). Vmax value was determined with the slope of the trendline. Experiment has been performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 10 SARS-CoV-2 peptide 50uM, cathepsin L recombinant protein 1.76ng/ul and AAT at l0 uM, were incubated together for 45 min. Fluorescence was measured every minute in a UV spectrophotometer (excitation at 330nm and emission detection at 390nm) (Figure 16 b). Vmax value was determined with the slope of the trendline. Experiment has been performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information. 76 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Example 11 SARS-CoV-2 peptide 50uM, trypsin recombinant protein 6.4nM and two concentrations of AAT (0.l uM and 1 uM) were incubated together for 45 min. Fluorescence was measured every minute in a UV spectrophotometer (excitation at 330nm and emission detection at 390nm)(Figure 16 c). Vmax value was determined with the slope of the trendline. Experiment has been performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 12 SARS-CoV-2 peptide 50uM, furin recombinant protein 10U/ml and AAT at l uM were incubated together for 45 min. Fluorescence was measured every minute in a UV spectrophotometer (excitation at 330nm and emission detection at 390nm) (Figure 16 d). Vmax value was determined with the slope of the trendline. Experiment has been performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 13 SARS-CoV-2 peptide 50uM, PCI recombinant protein 1.76ng/ul and several concentrations of AAT (l uM, l0 uM, 40 uM and l00 uM) were incubated together for 45 min. Fluorescence was measured every minute in a UV spectrophotometer (excitation at 330nm and emission detection at 390nm) (Figure 16 e). Vmax value was determined with the slope of the trendline.
Experiment has been performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 14 SARS-CoV-2 peptide 50uM, matriptase recombinant protein 1.76ng/ul and several concentrations of AAT (l uM, l0 uM, 40 uM and l00 uM) were incubated together for 45 min.
Fluorescence was measured every minute in a UV spectrophotometer (excitation at 330nm and emission detection at 390nm) (Figure 16 f). Vmax value was determined with the slope of the trendline. Experiment has been performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information. 77 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Example 15 AAT inhibits TMPRSS2 protease activity. Boc-QAR-AMC peptide 30 uM, TMPRSS2 recombinant protein 0.5 uM and AAT at 5 uM were incubated together for 45 min.
Fluorescence was measured every minute in a UV spectrophotometer (excitation at 380nm and emission detection at 460nm) (Figure 16 g). Vmax value was determined with the slope of the trendline. Experiment has been performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 16 DQ™ elastin substrate 25ug/mL, elastase (ELA1) from pig pancreas 0.25U/mL and several concentrations of AAT (l0 nM, 50nM and l00 nM) were incubated together for 45 min.
Fluorescence was measured every minute in a fluorescence reader (excitation at 485nm and emission detection at 530nm) (Figure 16 h). Vmax value was determined with the slope of the trendline. It was performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 17 Substrate MeOSuc-AAPV-pNA l00 uM, purified human neutrophil elastase (ELA2) 2.2uU/ul and several concentrations of AAT (1 nM and l0 nM) were incubated together for 45 min.
Absorbance was measured every minute in a spectrophotometer reader (A405nm) (Figure 16 i). Vmax value was determined with the slope of the trendline during 20 min. It was performed in duplicate. Error bars indicate the standard deviation. Please refer to material and method section for technical information.
Example 18 Titer measurement was done using an Octet RED (Sartorius, Octet RED96) method, Protein A biosensors (Sartorius, Ref 18-5010; 18-5012), Mouse Mc anti hAAT IgG2A (abcam, ab116604), neutralization buffer (MBD; 0,02% Tween 20, 150mM, NaCl,1mg/mL BSA, PBS1X) and regeneration buffer (MBD; 10mM Glycine- HCL (pH2)) binding as illustrated in Figure 26. Comparison between plasma derived AAT (Sigma-Aldrich, SRP6312) and recombinant AAT produced in CHO by PL136/PL137 pool (Figure 17). 78 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Example 19 Luc Human microglial cells HMC3-MHCII cells were plated at day 0, activated with IFNγ at day1 until day 2 and measurement of the luciferase activity and cell viability were done at day 4 (Figure 18 a). Activation was measured by the activity of MHCII-driven luciferase and normalized to cell viability. Luciferase activity for all conditions is represented as fold of the untreated cells control (Figure 18 b). All conditions were performed in triplicate, error bars represent standard deviation Example 20 Luc Luc AAT Human microglial HMC3-MHCII and HMC3-MHCII ;Ubi cells were plated at day 0, activated with IFNγ at day1 until day 2 and measurement of the luciferase activity and cell viability were measured at day 4. Plasma-derived AAT was applied from day 0 to day 4 on Luc HMC3-MHCII cells (Figure 19 a). Activation was measured by the activity of MHCII-driven luciferase and normalized to cell viability. Luciferase activity for all conditions is represented as percentage of IFNγ-activation control (Figure 19 b). All conditions were performed in triplicate, error bars represent standard deviation Example 21 Human microglial HMC3-MHCIILuc cells were plated at day 0, exposed to IFNγ and/or IFNβ at day 1 until day 2 and measurement of the luciferase activity and cell viability were done at day 4. Plasma-derived AAT was applied from day 0 to day 4 (Figure 20 a). Activation was measured by the activity of MHCII-driven luciferase and normalized to cell viability. 79 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Luciferase activity for all conditions is represented as percentage of IFNγ-activation control (Figure 20 b). Bars for plasma-derived AAT (1, 10, 25 µM) are repetition of Example 20 for comparison purpose. All conditions were performed in triplicate, error bars represent standard deviation.
Example 22 Coomassie Figure legend: SDS-PAGE coomassie-stained with AAT from multiple sources.educed samples were prepared for analysis by mixing with NuPage 4x LDS sample buffer (Life Technologies) and NuPage 10x sample reducing agent (Life Technologies), and incubated at 70°C, 10 min. For non-reduced samples, the reducing agent and heat incubation were omitted. 5ug of protein was loaded per lane. Samples were electrophoresed on 4-20% Mini- PROTEAN® Precast Gels (BioRad) with TGS buffer. Then gels were fixed for 30 minutes at room temperature in fixation buffer (50% Methanol + 10% acetic acid + 40% H2O).
Coomassie blue (Sigma Aldrich) was added at final concentration of 0.25% and incubated for additional 15 minutes. Finally gels were destained overnight in multiple washes of fixation buffer, and imaged on a G:Box imager (Syngene)(Figure 24).
Example 23 Expression of recombinant human AAT in HEK 293 cells. Based on the SEQ ID NO: 46 for HEK293 or SEQ ID NO: 47 for HEK293T. For HEK293 an rhAAT expression clone containing SERPINA1_OHu22141C_pcDNA3.1(+) plasmid was generated from the vector in Figure 25g.
The plasmid-containing clone was sequence verified and a sufficient amount of plasmid for transfection of HEK 293 cells (ATCC, Catalog# CRL-1573) was prepared. HEK293 cells were transfected with the plasmid and rhAAT expression and secretion into the culture broth in 3 sets of 6-well plates was confirmed using a commercially available ELISA kit (Thermo Fischer Scientific, Catalog# EH411RBX5). Mock transfected cells as well as cells transfected with pCMV-Td Tomato and EGFP fluorescent markers was used as a control. 80 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Critical materials and reagents used for generating rhAAT HEK 293 cells Materials and Supplier Catalog # Amount Purpose Reagents pcDNA™3.1(+) Thermo V79020 - Expression vector Fischer Scientific HEK-293 ATCC CRL-1573 - Host cells HyClone™ Thermo SH3024301 500mL Growth medium Dulbecco's Modified Fischer Eagles Medium Scientific Gibco™ Fetal Thermo 16-000-044 500mL Nutrient Bovine Serum, Fischer supplement certified, US Scientific Gibco™ Penicillin- Thermo 15-140-122 100mL Antibiotic Streptomycin Fischer supplement (10,000 U/mL) Scientific Gibco™ Versene Thermo 15-040-066 100mL Cell dissociation Solution Fischer reagent Scientific Gibco™ DPBS, no Thermo 14-190-250 500 mL Cell wash/dilution calcium, no Fischer buffer magnesium Scientific Gibco™ Thermo 10-131-035 20 mL Antibiotic solution Geneticin™ Fischer (selection agent) Selective Antibiotic Scientific (G418 Sulfate) (50 mg/mL) Lipofectamine™ Thermo 15338100 1.0 mL Transfection LTX Reagent with Fischer facilitating agent PLUS™ Reagent Scientific 81 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Materials and Supplier Catalog # Amount Purpose Reagents Human Serpin Thermo EH411RBX5 1 A1AT A3/Alpha-1- Fischer identity/quantitation Antichymotrypsin Scientific ELISA Kit rhAAT Select Resin 50mL Pellicon 10kDa Millipore membrane Pellicon 10kDa Millipore membrane PROCEDURE Production of rhAAT in HEK 293 cells was executed in two stages: 1. Preparation of rhAAT expressing cells. 2. Production of rhAAT.
Preparation of rhAAT expressing cells Preparation of rhAAT expressing cells included the following activities: - Construction and validation of expression-ready plasmid - Transfection of the host cells - Generation of rhAAT-expressing (stable) pools - Clone selection Construction and validation of expression-ready plasmid Based on the sequence presented in SEQ ID NO: 46, a rhAAT expression clone containing SERPINA1_OHu22141C_pcDNA3.1(+) plasmid was prepared by Genscript Biotech Corporation (Piscataway, NJ).
The plasmid-containing clone was shipped to RTI International (Research Triangle Park, NC) for sequence verification and preparation of a sufficient amount of plasmid for transfection of HEK 293 cells. 82 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Transient transfection of the host cells HEK293 cells were transfected with SERPINA1_OHu22141C_pcDNA3.1(+) plasmid and rhAAT expression and secretion into the culture broth in 3 sets of 6-well plates was confirmed using a commercially available ELISA kit. Mock transfected cells as well as cells transfected with pCMV-Td Tomato and EGFP fluorescent markers was used as a control.
Amounts of reagents and plasmid DNA per experiment per well L Plas Volum Total Opti- T mid Plasmi # of Plasmi PLUS Plasmids e/ well volum Mem X (ng/ d (µL) wells d (µL) (µL) (µL) e (µL) (µL) (µ µL) L) pcDNA3.1 1000 2.5 500 8 4000 3900 20.0 20.0 60 SERPINA 1 Mock 0 0 500 4 2000 1960 0.0 10.0 30 EGFP 308 8.1 500 2 1000 964 16.2 5.0 15 pCMV-Td 500 5.0 500 1 500 485 5.0 2.5 7.5 Tomato Generation of rhAAT-expressing (stable) pools Upon confirmation of successful transient transfection, generation of stable pools was performed in T-150 by antibiotic selection. The cells were maintained for up to 2 weeks under antibiotic selection to eliminate cells without plasmid. Following which, the culture supernatant was tested for protein expression using ELISA.
Pooled cells were frozen at 80°C prior to the transfer for further cell expansion and rhAAT production in shake flasks.
Clone selection Cells were harvested diluted and transferred to 10-cm2 dishes for isolating single clones. 3-6 clones from 50-96 colonies, depending on the behavior of the transgene, were identified for subsequent confirmation rhAAT expression by ELISA. 83 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Production of rhAAT Production of rhAAT includes cell expansion and rhAAT production in cell stacks, purification of rhAAT by affinity chromatography, product concentration and formulation (buffer exchange) utilizing Amicon Ultra 15, 10kDa tubes.
Cell expansion and rhAAT production in Cell Stacks Recombinant anchorage dependent HEK-293 cells were grown in culture treated T-flasks and Cell Staks bottles in Dulbecco’s Modified Eagles Medium (DMEM, HyClone) and supplemented with 10% fetal bovine serum (FBS, Gibco), Penicillin-Streptomycin (Gibco), and Geneticin Selective antibiotic G418 Sulfate (Gibco). The cultures were incubated in a humidified incubator at 37.0℃ and 5% CO and rotating at 2.5 rpm when grown in roller bottles 2 and subsequently harvested.
Purification of rhAAT by affinity chromatography Clarified culture supernatant was tested for pH and Conductivity and titrated to 7.4 ± 0.1 using 1M Tris, pH 7.4 and ±5 mS/cm of the equilibration buffer with 1M NaCl, respectively, as required. Following the pH and conductivity adjustment, the clarified supernatant was filterd through 0.2µm filter prior to purification.
Affinity chromatography The affinity chromatography column packed with rhAAT Select Resin was rinsed with 3CV of Purified Water and sanitized with 3CV 0.5 M NaOH (with a 30min hold after 2CV), followed by another rinse with 3CV of Purified Water and equilibration with 10CV 0f 20mM Tris, 150mM NaCl pH 7.4 buffer. The rhAAT Select column was loaded with the maximum volume of the clarified supernatant calculated based on rhAAT titer at the end of shake flask culture, volume of the clarified supernatant and the maximum column load capacity of 10mg/mL resin.
If required, in order to avoid overloading the resin, the clarified supernatant was processed through the rhAAT Select column in multiple cycles. Loaded protein was washed with 4CV of 20mM Tris, 150mM NaCl pH 7.4 buffer and rhAAT eluted with 4CV 0f 20mM Tris, 2 M MgCl pH 7.4 buffer into PETG collection bottles. The column was stripped with 4CV of PBS, pH 2.0 buffer and if required, equilibrated with 3CV of 20mM Tris, 150mM NaCl pH 7.4 buffer prior to performing additional cycles. 84 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] Example 24 Construction of the vectors PL136 (pCGS3_AAT_native_SP; Figure 25d) (original signal peptide into HindIII/XhoI restriction sites (LC MCS)) and PL137 (pCGS3_AAT_SP5, Figure 25e) (The singal peptide of SEQ ID NO:1 was optimized by replacing amino acids 1-24 with SM an ATUM (Newark, California) optimized signal peptide).
Coding sequences were codon optimized for expression in Chinese Hamster Ovary cells, using DNA2.0 proprietary algorithm (GeneGPS® Expression OptimizationTechnology, https://www.dna20.com/services/genegps). A canonical kozak sequence (GCCGCCACC) was added in front of the start codon. HindIII and XhoI restriction sites were added 5’ and 3’ of the synthetized coding sequences.
The resulting DNA fragments were cloned into vector pJ201. The complete plasmid map and sequence of clone pJ201_AAT_native_SP (Figure 25b) and pJ201_AAT_SP5 (Figure 25c) are provided. pCGS3_AAT_native_SP and pCGS3_AAT_SP5 were obtained according to the following cloning scheme (empty pCGS3 vector Figure 25f): Fragments preparation: 85 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] All digestions were incubated for 2 hour at 37°C. Fragments of interest were isolated by agarose gel electrophoresis (1.2% agarose gel). Fragments of expected size were excised, gel purified and used for the following ligations: The ligation mixtures (1 μl) were transformed into E. coli Stabl2 cells from Invitrogen. The transformed E. coli cells were cultivated on LB Agar Lennox, Animal Free containing 50 mg/l Carbenicillin. E. coli colonies were transferred into 4 ml LB Broth Lennox, Animal Free containing 50 mg/l Ampicillin and incubated over night at 33°C in a shaker incubator at 300 rpm. Plasmid DNA was isolated from the E. coli cultures using a Qiagen BioRobot 9600 and 86 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] the Nucleo Spin Robot-8 Plasmid kit from Macherey-Nagel. DNA was then sequenced using chains specific sequencing primers covering the cloning sites.
The sequences of the following clones were confirmed to be identical to the expected ones PL136 (pCGS3_AAT_native_SP; Figure 25d) and PL137 (pCGS3_AAT_SP5, Figure 25e).
AAT obtained from the PL136 in CHO and PL137 in CHO were pooled.
Example 25 Gene Synthesis and Single Gene Construction The rhAAT single gene vector was constructed by sub-cloning the product gene into the vector pXC-17.4 (Lonza) (Figure 25a).
DNA Amplification 1µL of vector DNA was used to transform One Shot® Stbl3 Chemically Competent E. coli cells (Life Technologies, C7373-03) using the heat-shock method according to manufacturer’s instructions. Cells were spread onto ampicillin-containing (50 µg/ml) LB agar plates (LB Broth Base, Select APS™ and Bacto-Agar, both Becton Dickinson, 292438 and 214010 respectively) and incubated overnight at 37°C until bacterial colonies were evident.
For Giga preps, single bacterial cultures were used to inoculate a starter culture which was subsequently used to inoculate 1.0 L Plasmid Plus Medium (Thomson, 446300) containing 50 µg ampicillin and incubated at 37°C overnight with shaking. Vector DNA was isolated using the QIAGEN Gigaprep system (Qiagen, 12291). In all instances, DNA concentration was measured using a Nanodrop 1000 spectrophotometer (Thermo-Scientific) and adjusted to 1mg/mL. DNA quality was assessed by measuring the absorbance ratio at 260 and 280 nm.
Routine Culture of CHOK1SV GS-KO Cells CHOK1SV GS-KO cells were cultured in CD-CHO media (Life Technologies, 10743-029) supplemented with 6mM L-glutamine (Life Technologies, 25030-123). Cells were incubated in a shaking incubator at 36.5°C, 5% CO2, 85% humidity, 140 rpm. Cells were routinely sub- cultured every 3-4 days, seeding at 0.2x106 cells/ml and were propagated in order to have sufficient cells available for transfection. Cells were discarded by passage 20.
Stable recombinant CHOK1SV GS-KO cells were cultured in CD-CHO media supplemented with 50 μM MSX (L-Methionine Sulfoximine, Sigma-Aldrich, M5379) and SP4. Cells were incubated in a shaking incubator at 36.5°C, 5% CO2, 85% humidity, 140 rpm. Cells were 87 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] routinely sub-cultured every 3-4 days, seeding at 0.2x 106 cells/ml and were propagated in order to have sufficient cells available for the large scale fed-batch overgrowth.
Stable Pooled Transfection of CHOK1SV GS-KO Cells Single gene vector DNA plasmid was prepared for transfection by linearising with PvuI followed by ethanol precipitation and resuspension in EB buffer to a final concentration of 400 µg/ml. Transfection was carried out via electroporation using the Gene Pulse XCell. For each transfection, viable cells were resuspended in pre-warmed CD-CHO media to 1.43x 107 cells/ml. 100 µl linearised DNA at a concentration of 400 µg/ml was aliquotted into a 0.4 cm gap electroporation cuvette and 700 µl cell suspension added. Three cuvettes of cells and DNA were electroporated at 300 V, 900 µF and immediately recovered to 30 ml pre-warmed CD- CHO supplemented with 10 ml/L SP4 (Lonza, BESP1076E) to generate a stable pool. The transfectants were incubated in a shaking incubator at 36.5°C, 5% CO2, 85% humidity, 140 rpm.
A total of 3 stable pool transfectants were established. 24 h post-transfection the cultures were centrifuged and resuspended into pre-warmed CD-CHO supplemented with 50 µM MSX and ml/L SP4. Cell growth and viability were periodically checked post- transfection.
When the viable cell density was >0.6x 106 cells/ml, the transfectant cultures were suitable to progress. Cells were seeded at 0.2x 106 cells/ml in a final volume of 100 ml in CD-CHO medium supplemented with 50 µM MSX/ 10 ml/L SP4, in a 500 ml vented Erlenmeyer flask (Fisher Scientific (Corning), 10352742) and incubated in a shaking incubator at 36.5°C, 5% CO2, 85% humidity, 140 rpm. Cell cultures were monitored and expanded once cultures had adapted to exponential growth. Cultures were expanded to 200 ml culture volume in 500 ml vented Erlenmeyer flasks at a concentration of 0.2x 106 cells/ml in CD- CHO supplemented with 50 µM MSX/10 ml/L SP4 and incubated under the conditions described above (see Section 0). Cultures were then expanded to the appropriate production volume.
Abridged Fed-Batch Overgrow Cells were propagated to production volume of 2 L per product by seeding the appropriate culture volume at 0.2x 106 cells/mL in Lonza’s CM42 base media supplemented with 4 mL/L SPE from the established stable pools. The production volumes were established in 5 L (Generon, 931116) shake flasks and incubated in a shaking incubator at 36.5°C, 5% CO2, 85% humidity, and 140 rpm. Cell count and viability were monitored on day 4, before feeding was 88 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] initiated and periodically until the culture was harvested on day 11. The bolus feeds were administered on day 4 and 8 consisting of a mixture of Lonza’s proprietary feeds.
Harvesting and Concentrating of Production Culture The culture was harvested by centrifugation at 3000 rpm for 10 min and filtered using a 0.22 µm PES membrane to obtain clarified supernatant.
Alpha-1 anti-trypsin Affinity Chromatography The clarified cell supernatant was purified using an in-house packed 50 ml Alpha-1 anti- trypsin Select column (GE Healthcare). The column was equilibrated pre- and post- product application with 20mM Tris, 150mM NaCl, pH 7.4 and elution was carried out with 20mM Tris, 2 M MgCl2, pH 7.4. The procedure was carried out on an AKTA Purifier at 10 ml/min. Product- containing fractions from the affinity chromatography eluate were pooled and buffer exchanged into 50mM Tris, 75mM NaCl, pH 8.0 by Tangential Flow Filtration (TFF) using Spectrum’s KrosFlo TFF system with a 10 kDa MWCO (D02-E010-05-N).
Anion Exchange Chromatography The pooled and buffer exchanged fractions were further purified using 25 ml CaptoQ column (5x 5ml columns connected in tandem) (GE Healthcare) on an AKTA purifier at 10 ml/min.
The column was equilibrated pre- and post- product application with 50mM Tris, 75mM NaCl, pH 8.0. The product was eluted over a 10 CV linear gradient to 50mM Tris, 1 M NaCl, pH 8.0.
Product-containing fractions from the anion exchange chromatography eluate were pooled, diluted 1 mg/ml and quality analysed.
SE-HPLC Duplicate samples were analysed by SE-HPLC on an Agilent 1200 series HPLC system, using a Zorbax GF-250 9.4mM ID x 25 cm column (Agilent). 80 µL aliquots of 1 mg/mL samples (or stock concentration if samples are < 1 mg/mL) were injected and run in 50mM sodium phosphate, 150mM sodium chloride, 500mM arginine, pH 6.0 at 1 mL/min for 15 minutes.
Soluble aggregate levels were analysed using Empower software. Signals arising from buffer constituents were analysed by blank buffer injection and are omitted in the data analysis unless indicated otherwise.
Product concentration The purified product was concentrated to a target of 25mg/mL using Vivaspin Turbo-15 Centrifugal Filter Units 30KDa Molecular Weight Cut-Off (Sartorius, VS15T02). 89 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] REFERENCES 1. Wrapp, D., et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020. 367(6483): p. 1260-1263. 2. Jaimes, J.A., J.K. Millet, and G.R. Whittaker, Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. iScience, 2020. 23(6): p. 101212. 3. Korber, B., et al., Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv, 2020: p. 2020.04.29.069054. 4. Becerra-Flores, M. and T. Cardozo, SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int J Clin Pract, 2020. 5. Li, Q., et al., The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell, 2020. 6. Ogawa, J., et al., The D614G mutation in the SARS-CoV-2 Spike protein increases infectivity in an ACE2 receptor dependent manner. bioRxiv, 2020. 7. Goodfellow, I. Goodfellow, and S.I. Taube, Calicivirus Replication and Reverse Genetics Viral Gastroenteritis : Molecular Epidemiology and Pathogenesis. 2016: p. 355-378. 8. Yin, W., et al., Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science, 2020. 9. Gao, Y., et al., Structure of the RNA-dependent RNA polymerase from COVID-19 virus.
Science, 2020. 368(6492): p. 779-782.
. Pachetti, M., et al., Emerging SARS-CoV-2 mutation hot spots include a novel RNA- dependent-RNA polymerase variant. J Transl Med, 2020. 18(1): p. 179. 90 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0]
Claims (28)
1. A composition for use in the treatment and/or prevention of a disease or syndrome 5 related to a virus infection in a subject in need thereof, the composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof.
2. The composition for use according to claim 1, wherein the subject in need thereof has 10 at least one selected from the group consisting of: 1. a lower level of endogenous alpha-antitrypsin (AAT) prior to a virus infection or during a virus infection compared to at least one subject during a virus infection, which is asymptomatic or has mild symptoms 15 2. a higher level of at least one spike protein priming protease prior to a virus infection or during a virus infection compared to at least one subject during a virus infection, which is asymptomatic or has mild symptoms, 3. a higher level of angiotensin converting enzyme 2 (ACE2 receptor) in a subject prior to a virus infection or during a virus infection compared to at least one 20 subject during a virus infection, which is asymptomatic or has mild symptoms, and 4. a higher level of interferon-gamma (IFN-γ) in a subject prior to a virus infection or during a virus infection compared to at least one subject during a virus infection, which is asymptomatic or has mild symptoms. 25
3. The composition for use according to claim 2, wherein the lower level of endogenous AAT prior to a virus infection or during a virus infection is caused by AAT-deficiency.
4. The composition for use according to claim 2 or 3, wherein the spike protein priming 30 protease is at least one selected from the group consisting of transmembrane protease serine subtype 2 (TMPRSS2), transmembrane protease subtype 6 (TMPRSS6), cathepsin L, cathepsin B, proprotein convertase 1 (PC1), trypsin, elastase, neutrophil elastase, matriptase and furin, preferably cathepsin L and furin. 91 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0]
5. The composition for use according to any of the claims 2 to 4, wherein the higher level of at least one spike protein priming protease is caused by age and/or a genetic predisposition. 5
6. The composition for use according to any of the claims 2 to 5, wherein the higher level of ACE2 receptor is caused by at least one selected from the group of an infection, inflammation, age and a genetic predisposition.
7. The composition for use according to any of the claims 2 to 6, wherein the higher level 10 of IFN-γ is caused by at least one selected from the group of an infection, inflammation, age and a genetic predisposition.
8. The composition for use according to any of the claims 2 to 7, wherein the subject in need thereof has 15 i) a lower level of endogenous AAT, and ii) a higher level of at least one spike protein priming protease.
9. The composition for use according to any of the claims 2 to 8, wherein the subject in need thereof has 20 i) a lower level of endogenous AAT and iii) a higher level of ACE2 receptor.
10. The composition for use according to any of the claims 2 to 9, wherein the subject in need thereof has 25 i) a lower level of endogenous AAT and iv) a higher level of IFN-γ.
11. The composition for use according to claim 10, wherein the higher level of IFN-γ is caused by at least one disease or condition selected from the group consisting of AAT- 30 deficiency, a liver disease such as a non-alcoholic fatty liver disease, diabetes, obesity and a cardiovascular condition.
12. The composition for use according to any of the claims 2 to 11, wherein the subject in need thereof has 92
13.DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] i) a lower level of endogenous AAT, ii) a higher level of at least one spike protein priming protease, and iii) a higher level of ACE2 receptor and/or iv) a higher level of IFN-γ. 5 13. The composition for use according to any one of the preceding claims, wherein the alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is human plasma-extracted.
14. The composition for use according to any one of the claims 1 to 12, wherein the alpha1- 10 antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof is recombinant alpha1-antitrypsin (rhAAT), a variant, an isoform and/or a fragment thereof.
15. The composition for use according to claim 14, wherein the alpha1-antitrypsin protein 15 is as set forth in SEQ ID NO:. 1.
16. The composition for use according to claim 14, wherein the alpha1-antitrypsin fragment is a C-terminal sequence fragment, or any combination thereof. 20
17. The composition for use according to claim 14, wherein the alpha1-antitrypsin variant is selected from the group comprising short cyclic peptides derived from the C-terminal sequence as set forth in SEQ ID NO: 2.
18. The composition for use according to claim 17, wherein the short cyclic peptides derived 25 from the C-terminal sequence of Alpha1-Antitrypsin is selected from the group comprising Cyclo-(CPFVFLM)-SH, Cyclo-(CPFVFLE)-SH, Cyclo-(CPFVFLR)-SH, and Cyclo-(CPEVFLM)-SH, or any combination thereof.
19. The composition for use according to any of the previous claims, wherein the 30 composition further comprises a pharmaceutically acceptable excipient or carrier.
20. The composition for use according to any of the previous claims, wherein the composition further comprises a nucleoside analog, a protease inhibitor, an immune- suppressor (e.g. sarilumab or tocilizumab), an antibiotic, an antibody directed 93 DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] against structural components of the virus, or fragment thereof (e.g. passive immunotherapy), interferon beta (e.g. interferon beta-1a), and/or a vaccine.
21. The composition for use according to any one of the preceding claims wherein said 5 composition is administered by intravenous injection, intravenous infusion, infusion with a dosator pump, inhalation nasal-spray, eye-drops, skin-patches, slow release formulations, ex vivo gene therapy or ex vivo cell-therapy, preferably by intravenous injection. 10 22. A method for determining the susceptibility of a subject of interest for treatment and/or prevention of a disease or syndrome related to a virus infection using a composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof as defined in any of claims 1 to 21, comprising the steps of: 15 a) determining the level of at least one of the group comprising endogenous alpha1- antitrypsin, at least one spike protein priming protease, ACE2 receptor and interferon-gamma in the subject of interest prior to a virus infection or during a virus infection, b) determining the level of at least one of the group comprising endogenous alpha1- 20 antitrypsin, at least one spike protein priming protease, ACE2 receptor and interferon-gamma in at least one reference subject during a virus infection, wherein the reference subject is asymptomatic or has mild symptoms, c) comparing the level of interest determined in step a) to the reference level determined in step b), 25 wherein the subject of interest is more susceptible for treatment and/or prevention of a disease or syndrome related to a virus infection if the subject of interest has at least one selected from the group consisting of: 1. a lower level of interest of endogenous alpha-antitrypsin (AAT) compared to the reference level of endogenous AAT, 30 2. a higher level of interest of at least one spike protein priming protease compared to the reference level of at least one spike protein priming protease, 3. a higher level of interest of angiotensin converting enzyme 2 (ACE2 receptor) compared to the reference level of the ACE2 receptor and 94
22.DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 4. a higher level of interest of interferon-gamma (IFN- γ) compared to the reference level of IFN-γ.
23. A method for determining the therapeutically effective amount of alpha1-antitrypsin 5 (AAT) for an effective treatment and/or prevention of a disease or syndrome related to a virus infection using the composition according to any of the claims 1 to 21 comprising the steps of: a) determining the level of endogenous alpha1-antitrypsin in a subject of interest prior to a virus infection or during a virus infection, 10 b) determining the amount of AAT in the composition, which is required to achieve a level of AAT in the subject of at least 10 µM, preferably at least 20 µM, more preferably at least 50 µM, even more preferably at least 100 µM, and most preferably at least 200 µM. 15
24. The composition for use according to any one of the claims 1 to 21, or the method according to claim 22 and 23, wherein the virus is a coronavirus.
25. The composition for use according to claim 24, or the method according to claim 24, wherein the virus is a SARS-CoV-2. 20
26. The composition for use according to any one of the claims 1 to 25, or the method according to claims 22 to 25, wherein the disease or syndrome is a respiratory syndrome or a severe acute respiratory syndrome. 25
27. The composition for use according to any one of the claims 1 to 25, or the method according to claims 22 to 25, wherein the disease or syndrome is an inflammatory disease or syndrome of the nervous system.
28. The composition for use according to any one of the claims 1 to 27, or the method 30 according to claim 27, wherein the inflammatory disease or syndrome of the nervous system is a disease or syndrome selected from the group of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease. 95 DynamicPDF for .NET v8.0.0.40 (Build 29393)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20172564 | 2020-05-01 | ||
EP20192016 | 2020-08-20 | ||
PCT/EP2021/061597 WO2021219896A1 (en) | 2020-05-01 | 2021-05-03 | Treatment and/or prevention of a disease or a syndrome related to a virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
IL297741A true IL297741A (en) | 2022-12-01 |
Family
ID=83807521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL297741A IL297741A (en) | 2020-05-01 | 2021-05-03 | Treatment and/or prevention of a disease or a syndrome related to a virus infection |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230302104A1 (en) |
EP (1) | EP4142775A1 (en) |
JP (1) | JP2023523652A (en) |
KR (1) | KR20230005965A (en) |
CN (1) | CN116033917A (en) |
AU (1) | AU2021263106A1 (en) |
CA (1) | CA3174939A1 (en) |
IL (1) | IL297741A (en) |
MX (1) | MX2022013309A (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314447C (en) * | 2004-04-12 | 2007-05-09 | 爱华生物科技(香港)有限公司 | Method for preparing medicine with proteinase inhibiting function and its detecting method |
WO2013098672A2 (en) * | 2011-12-30 | 2013-07-04 | Grifols, S.A. | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations |
WO2016145217A1 (en) * | 2015-03-10 | 2016-09-15 | The Trustees Of Columbia University In The City Of New York | Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression |
-
2021
- 2021-05-03 EP EP21723704.9A patent/EP4142775A1/en active Pending
- 2021-05-03 JP JP2023509874A patent/JP2023523652A/en active Pending
- 2021-05-03 AU AU2021263106A patent/AU2021263106A1/en active Pending
- 2021-05-03 CN CN202180046138.3A patent/CN116033917A/en active Pending
- 2021-05-03 US US17/922,269 patent/US20230302104A1/en active Pending
- 2021-05-03 IL IL297741A patent/IL297741A/en unknown
- 2021-05-03 KR KR1020227042186A patent/KR20230005965A/en active Search and Examination
- 2021-05-03 MX MX2022013309A patent/MX2022013309A/en unknown
- 2021-05-03 CA CA3174939A patent/CA3174939A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022013309A (en) | 2022-11-14 |
CN116033917A (en) | 2023-04-28 |
JP2023523652A (en) | 2023-06-06 |
CA3174939A1 (en) | 2021-11-04 |
KR20230005965A (en) | 2023-01-10 |
US20230302104A1 (en) | 2023-09-28 |
AU2021263106A1 (en) | 2022-11-03 |
EP4142775A1 (en) | 2023-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nordmann et al. | A new splice variant of the human guanylate‐binding protein 3 mediates anti‐influenza activity through inhibition of viral transcription and replication | |
EP2678355B1 (en) | Novel superactive il-33 fragments, and uses thereof | |
JP2019513752A (en) | Mitochondrial localization inhibitor of TDP-43 for treating neurodegenerative diseases | |
AU2015374043A1 (en) | Methods and compositions for treating brain diseases | |
JP2014533961A (en) | Modified stem cells and their therapeutic use | |
JP7037486B2 (en) | Use of human-derived immunosuppressive proteins and peptides as pharmaceuticals | |
US20230302104A1 (en) | Treatment and/or prevention of a disease or a syndrome related to a virus infection | |
KR20220095183A (en) | Compositions and methods for treating viral infections | |
US20240207377A1 (en) | Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders | |
WO2021219896A1 (en) | Treatment and/or prevention of a disease or a syndrome related to a virus infection | |
WO2020124229A1 (en) | Stabilized osteocalcin and uses thereof | |
WO2017162704A1 (en) | Inhibitors of fpr2, compositions and uses thereof for modulating influenza virus replication | |
KR20200039621A (en) | Compositions and methods for the treatment of myelin disorder | |
KR20170093033A (en) | Pharmaceutical Composition for Preventing or Treating Influenza Virus Infection Disease | |
JP6993720B2 (en) | Antiviral agent | |
US20230331815A1 (en) | Methods and compositions for treating viral infection | |
US20100291120A1 (en) | Peptides regulating the surface expression of the t cell receptor | |
WO2015050170A1 (en) | Influenza virus inhibitory drug | |
Zheng et al. | Interleukin-1 prevents SARS-CoV-2-induced membrane fusion to restrict viral transmission via induction of actin bundles | |
CN117222424A (en) | Alpha-1-antitrypsin (AAT) for the treatment and/or prophylaxis of neurological disorders | |
EP4221747A2 (en) | Clec2 fusion protein and uses thereof | |
Liu | Dissecting the Novel Roles of TRIM56 in Antiviral Innate Immunity | |
LYON et al. | o LICATION | |
Overall et al. | Heterogeneous nuclear ribonucleoprotein M facilitates enterovirus 7 infection 8 | |
JP2012006852A (en) | Treating and/or onset inhibiting agent for influenza virus infection |